{"id":69,"date":"2019-10-20T00:00:29","date_gmt":"2019-10-20T00:00:29","guid":{"rendered":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/2-3-legal-foundations-and-national-guidelines-for-safe-medication-administration\/"},"modified":"2025-01-16T22:29:14","modified_gmt":"2025-01-16T22:29:14","slug":"2-3-legal-foundations-and-national-guidelines-for-safe-medication-administration","status":"publish","type":"chapter","link":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/2-3-legal-foundations-and-national-guidelines-for-safe-medication-administration\/","title":{"raw":"2.3 Legal Foundations and National Guidelines for Safe Medication Administration","rendered":"2.3 Legal Foundations and National Guidelines for Safe Medication Administration"},"content":{"raw":"Many federal and state laws, as well as national guidelines, have been established to protect public health and safety related to medication administration. This section will explain how federal and state laws, agencies, and guidelines protect clients from harm from medications.\n<h2>Federal Agencies, Laws, and Guidelines<\/h2>\n<h3>Food and Drug Administration<\/h3>\nThe United States Food and Drug Administration (FDA) protects public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices, as well as the safety of our nation's food supply, cosmetics, and products that emit radiation.<sup>[footnote]U.S. Food and Drug Administration. (n.d). <a href=\"https:\/\/www.fda.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.fda.gov<\/a>[\/footnote]<\/sup> The FDA protects public health by enforcing an official drug approval process based on evidence-based research and issuing Boxed Warnings for medications with serious adverse reactions. These actions are further discussed in the following subsections.\n<h4><a id=\"_3mwn8iw3zliz\" href=\"\"><\/a>Developing New Drugs<\/h4>\nAmerican consumers benefit from having access to the safest and most advanced pharmaceutical system in the world. The main consumer watchdog in this system is the FDA's Center for Drug Evaluation and Research (CDER). The center's best-known job is to evaluate new drugs before they can be sold. CDER's evaluation not only prevents misinformation from being provided to the public, but also provides doctors and clients the information they need to use medicines wisely. CDER ensures that drugs, both brand-name and generic, work correctly and their health benefits outweigh their known risks.\n\nDrug companies conduct extensive research and work to develop and test a drug. The company then sends CDER the evidence from these tests to prove the drug is safe and effective for its intended use. Before the drug is approved as safe for use in the United States, a team of CDER physicians, statisticians, chemists, pharmacologists, and other scientists reviews the company's data and proposed labeling. If this independent and unbiased review establishes a drug's health benefits outweigh its known risks, the drug is approved for sale. Before a drug can be tested in people, the drug company or sponsor performs laboratory and animal tests to discover how the drug works and whether it's likely to be safe and work well in humans. Next, a series of clinical trials involving volunteers is conducted to determine whether the drug is safe when used to treat a disease and whether it provides a real health benefit.\n<div class=\"textbox\">\n<p class=\"arrow\">Visit the FDA's \"<a href=\"https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\" target=\"_blank\" rel=\"noopener\">Development and Approval Process | Drugs\" webpage<\/a>.<\/p>\n\n<\/div>\n<h4><a id=\"_id4s01tcl6zm\" href=\"\"><\/a>FDA Approval of a Drug<\/h4>\nFDA approval of a drug means that data on the drug's effects have been reviewed by the CDER, and the drug is determined to provide benefits that outweigh its known and potential risks for the intended population. The drug approval process takes place within a structured framework that includes the following:\n<ul>\n \t<li><strong>Analysis of the target condition and available treatments:<\/strong> FDA reviewers analyze the condition or illness for which the drug is intended and evaluate the current treatment landscape, which provide the context for weighing the drug's risks and benefits. For example, a drug intended to treat clients with a life-threatening disease for which no other therapy exists may be considered to have benefits that outweigh the risks even if those risks would be considered unacceptable for a condition that is not life-threatening.<\/li>\n \t<li><strong>Assessment of benefits and risks from clinical data:<\/strong> FDA reviewers evaluate clinical benefit and risk information submitted by the drug maker, taking into account any uncertainties that may result from imperfect or incomplete data. Generally, the agency expects that the drug maker will submit results from two well-designed clinical trials to be sure the findings from the first trial are not the result of chance or bias. In certain cases, especially if the disease is rare and multiple trials may not be feasible, convincing evidence from one clinical trial may be enough. Evidence that the drug will benefit the target population should outweigh any risks and uncertainties.<\/li>\n \t<li><strong>Strategies for managing risks:<\/strong> All drugs have risks. Risk management strategies include an FDA-approved drug label, which clearly describes the drug's benefits and risks and information pertaining to the detection and management of any risks. Sometimes, more effort is needed to manage risks. In these cases, a drug maker may need to implement a Risk Evaluation and Mitigation Strategy (REMS).<\/li>\n<\/ul>\nAlthough many of the FDA's risk-benefit assessments and decisions are straightforward, sometimes the benefits and risks are uncertain and may be difficult to interpret or predict. The agency and the drug maker may reach different conclusions after analyzing the same data, or there may be differences of opinion among members of the FDA's review team. As a science-led organization, the FDA uses scientific and technological information to make decisions through a deliberative process.<sup>[footnote]U.S. Food and Drug Administration. (n.d.). <em>Developing new drugs.<\/em> <a href=\"https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs<\/a>[\/footnote]<\/sup>\n<h4><a id=\"_t0376x72b8jl\" href=\"\"><\/a>Boxed Warnings<\/h4>\nAs discussed in the previous subsection, the FDA approves a drug after determining that the drug's benefits of use outweigh the risks for the condition that the drug will treat. However, even with the rigorous FDA evaluation process, safety problems can surface after a drug has been on the market and used in a broader population.\n\n<strong>[pb_glossary id=\"623\"]Boxed Warnings[\/pb_glossary]<\/strong> (formerly known as Black Box Warnings) are the highest safety-related warning that medications can have assigned by the FDA. These warnings are intended to bring the consumer\u2019s attention to the major risks of the drug. Medications can have a boxed warning added, taken away, or updated throughout their tenure on the market. Boxed Warnings appear on a prescription drug's label and in current, evidence-based drug references. For this reason, it is important for nurses to verify current drug information in drug references.\n<div class=\"textbox textbox--examples\"><header class=\"textbox__header\">\n<h2><img class=\"alignright wp-image-67 size-thumbnail\" src=\"https:\/\/pressbooks.ccconline.org\/accdigitalmarketing\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-150x150.png\" alt=\"Image of a circle containing a speech bubble with a question mark in it.\" width=\"150\" height=\"150\">Critical Thinking Activity 2.3a<\/h2>\n<\/header>\n<div class=\"textbox__content\">\n\nLevofloxacin is an antibiotic that received FDA approval. However, after the drug was on the market, it was discovered that some clients who took levofloxacin developed serious, irreversible adverse effects such as tendon rupture. The FDA issued a Boxed Warning with recommendations to reserve levofloxacin for use in clients who have no alternative treatment options for certain indications: uncomplicated UTI, acute exacerbation of chronic bronchitis, and acute bacterial sinusitis.<sup>[footnote]This work is a derivative of <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\" target=\"_blank\" rel=\"noopener noreferrer\">DailyMed<\/a> by <a href=\"https:\/\/www.nlm.nih.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a> in the <a href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\" target=\"_blank\" rel=\"noopener noreferrer\">Public Domain<\/a>.[\/footnote]<\/sup>\n\nA nurse is preparing to administer medications to a client and notices that levofloxacin has been prescribed for the indication of pneumonia. There is no other documentation in the provider's notes related to the use of this medication.\n\nWhat is the nurse's best response?\n\nNote: Answers to the Critical Thinking activities can be found in the \u201c<a href=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/chapter-2\/\" target=\"_blank\" rel=\"noopener\">Answer Key<\/a>\u201d section at the end of the book.\n\n<\/div>\n<\/div>\n<h3>U.S. Drug Enforcement Agency (DEA)<\/h3>\nThe U.S. Drug Enforcement Agency (DEA) enforces the federal laws and regulations of controlled substances. This includes enforcement of the Controlled Substances Act (CSA) that pertains to the manufacture, distribution, and dispensing of legally produced controlled substances that nurses administer to clients.<sup>[footnote]U.S. Department of Justice - Drug Enforcement Administration. (n.d.). <em>Drug scheduling. <\/em><a href=\"https:\/\/www.dea.gov\/drug-scheduling\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.dea.gov\/drug-scheduling<\/a>[\/footnote]<\/sup>\n\nBecause controlled substances have a greater chance of being misused and abused, there are additional laws and procedures that must be followed when working with these medications. The DEA is responsible for enforcing these laws, and many federal laws are summarized in a document called the <em>Pharmacist's Manual<\/em>. Most controlled substance laws, however, come from state governments. Health care professionals are responsible for following the most stringent of the two laws, whether it be state law or federal law.\n<div class=\"textbox\">\n<p class=\"arrow\">View the DEA's <a href=\"https:\/\/www.deadiversion.usdoj.gov\/GDP\/%28DEA-DC-046R1%29%28EO-DEA154R1%29_Pharmacist%27s_Manual_DEA.pdf\" target=\"_blank\" rel=\"noopener\">Pharmacist's Manual<\/a> PDF.<\/p>\n\n<\/div>\n<h4>Examples of Federal and State Laws Regarding Controlled Substances<\/h4>\nThe following examples of federal laws are applicable to controlled substances administered by nurses:\n<ul>\n \t<li><strong>Prescriptions:<\/strong> A prescription for a controlled substance may be written only by a provider (physician or mid-level provider such as a nurse practitioner) who has a DEA registration number. The prescription for a Schedule II medication (i.e., opioids) must be written or electronically sent to the pharmacy through DEA approved software. Prescriptions over the phone or fax are not accepted. Refills for Schedule II medication are not allowed and require new prescriptions. Schedule III or IV medications may be refilled only five times. State law determines how long a written Schedule II prescription is valid and if there are any limits on the quantity of medication that can be dispensed. For example, in Wisconsin, a Schedule II prescription is only valid for 60 days after it is written.<\/li>\n \t<li><strong>Records:<\/strong> There is a \u201cclosed system\u201d for record keeping of controlled substances to prevent drug diversion. Hospitals, clinics, and pharmacies must maintain records on the whereabouts of controlled substances from the time the medication is received by the pharmacy, to when it is administered to the client, to disposal of wasted medication by the nurse. Inventory counts of controlled substances occur frequently and may require a physical count by two licensed staff at the start of each shift. Detailed documentation is required for administration of controlled substances. When a full dose of a controlled substance is not administered, this is referred to as waste. Waste is typically disposed of differently than other medications (i.e., flushed down the sink) and often requires the co-signature of a second licensed staff member.<\/li>\n<\/ul>\n<div class=\"textbox\">\n<p class=\"arrow\">View the\u00a0<a href=\"https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/phar\/8.pdf\" target=\"_blank\" rel=\"noopener\">Requirements for Controlled Substances PDF<\/a><span style=\"font-size: 12.8px\">[footnote]Wisconsin Administrative Code. (2022).\u00a0<\/span><em style=\"font-size: 12.8px\">Uniform Controlled Substances Act.\u00a0<\/em><a style=\"font-size: 12.8px\" href=\"https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/phar\/8.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/phar\/8.pdf<\/a><span style=\"font-size: 12.8px\">[\/footnote]<\/span> with additional information about Wisconsin state laws regarding controlled substances.<\/p>\n\n<\/div>\n<h4><a id=\"_tj7fz92l0928\" href=\"\"><\/a>Schedules of Drugs<\/h4>\nThe federal Controlled Substances Act (CSA) categorizes drugs regulated under federal law into one of five schedules. This placement is based on the substance's medical use, potential for abuse, and safety or dependence liability. Schedule I drugs have a high potential for abuse and the potential to create severe psychological and\/or physical dependence, whereas Schedule V drugs represent the least potential for abuse. Sample medications for each schedule are summarized in Table 2.3.<sup>[footnote]U.S. Department of Justice - Drug Enforcement Administration. (n.d.). <em>Drug scheduling.<\/em> <a href=\"https:\/\/www.dea.gov\/drug-scheduling\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.dea.gov\/drug-scheduling<\/a>[\/footnote]<\/sup>\n\nTable 2.3 Definitions and Sample Medications for Each Type of Scheduled Medication\n<table class=\"grid\">\n<tbody>\n<tr>\n<th class=\"shaded\" scope=\"col\">\n<h5><strong>Schedule<\/strong><\/h5>\n<\/th>\n<th class=\"shaded\" scope=\"col\">\n<h5><strong>Definition<\/strong><\/h5>\n<\/th>\n<th class=\"shaded\" scope=\"col\">\n<h5><strong>Examples<\/strong><\/h5>\n<\/th>\n<\/tr>\n<tr>\n<th scope=\"row\">Schedule\u00a0I<\/th>\n<td>No currently accepted medical use and a high potential for abuse.<\/td>\n<td>Heroin, LSD, and marijuana<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Schedule\u00a0II<\/th>\n<td>High potential for abuse, with use potentially leading to severe psychological or physical dependence. These drugs are also considered dangerous.<\/td>\n<td>Vicodin, cocaine, methamphetamine, methadone, hydromorphone (Dilaudid), meperidine (Demerol), oxycodone (OxyContin), fentanyl, Dexedrine, Adderall, and Ritalin<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Schedule\u00a0III<\/th>\n<td>Moderate to low potential for physical and psychological dependence. Abuse potential is less than Schedule I and Schedule II drugs but more than Schedule IV.<\/td>\n<td>Tylenol with codeine, ketamine, anabolic steroids, and testosterone<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Schedule\u00a0IV<\/th>\n<td>Low potential for abuse and low risk of dependence.<\/td>\n<td>Xanax, Soma, Valium, Ativan, Talwin, Ambien, and Tramadol<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Schedule\u00a0V<\/th>\n<td>Lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics. Generally used for antidiarrheal, antitussive, and analgesic purposes.<\/td>\n<td>Robitussin AC with codeine, Lomotil, and Lyrica<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div class=\"textbox\">\n<p class=\"arrow\">Read more information about <a href=\"https:\/\/www.dea.gov\/drug-scheduling\" target=\"_blank\" rel=\"noopener\">Drug Scheduling<\/a> on the DEA website and view an alphabetic listing of drugs and their schedule.<sup>[footnote]U.S. Department of Justice - Drug Enforcement Administration. (n.d.). <em>Drug scheduling. <\/em><a href=\"https:\/\/www.dea.gov\/drug-scheduling\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.dea.gov\/drug-scheduling<\/a>[\/footnote],[footnote]U.S. Department of Justice - Drug Enforcement Administration. (2023).<em> Controlled substances. <\/em><a href=\"https:\/\/www.deadiversion.usdoj.gov\/schedules\/orangebook\/c_cs_alpha.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.deadiversion.usdoj.gov\/schedules\/orangebook\/c_cs_alpha.pdf<\/a>[\/footnote]<\/sup><\/p>\n\n<\/div>\nDrug overdose continues to be a public health crisis in the United States. The misuse of prescription opioids contributes to a large percentage of overdose deaths. Many problems associated with substance use are the result of legitimately made controlled substances being diverted from their lawful purpose into illicit drug traffic. The mission of DEA's Diversion Control Division is to prevent, detect, and investigate the diversion of controlled medications from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs. The DEA provides education regarding related topics that apply to nurses such as drug diversion, state prescription drug monitoring systems, current drug trends, and proper drug disposal.<sup>[footnote]U.S. Department of Justice - Drug Enforcement Administration. (2023). <em>Controlled substances. <\/em><a href=\"https:\/\/www.deadiversion.usdoj.gov\/schedules\/orangebook\/c_cs_alpha.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.deadiversion.usdoj.gov\/schedules\/orangebook\/c_cs_alpha.pdf<\/a>[\/footnote]<\/sup>\n<h4><a id=\"_uofazniim8wd\" href=\"\"><\/a>Drug Diversion<\/h4>\nDrug diversion involves the transfer of any legally prescribed controlled substance from the individual for whom it was prescribed to another person for any illicit use. The most commonly diverted substances in health care facilities are opioids. Diversion of controlled substances can result in substantial risk, not only to the individual who is diverting the drugs, but also to clients, coworkers, and employers. Impaired health professionals can harm clients by providing substandard care or exposing clients to tainted substances.\n\nTampering is the riskiest and most harmful type of diversion. Tampering occurs when the diverter removes medication from a syringe, vial, or other container and injects themselves with the medication. The diverter then replaces the stolen medication with saline, sterile water, or another clear liquid. The replaced liquid is then unknowingly administered to the client by an unaware nurse.<sup>[footnote]New, K. (2014, June 3). <em>Drug diversion defined: A patient safety threat.<\/em> Centers for Disease Control and Prevention. <a href=\"https:\/\/web.archive.org\/web\/20150716073835\/http:\/\/blogs.cdc.gov\/safehealthcare\/2014\/06\/03\/drug-diversion-defined-a-patient-safety-threat\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/web.archive.org\/web\/20150716073835\/http:\/\/blogs.cdc.gov\/safehealthcare\/2014\/06\/03\/drug-diversion-defined-a-patient-safety-threat\/<\/a>[\/footnote],[footnote]Berge, K. H., Dillon, K. R., Sikkink, K. M., Taylor, T. K., &amp; Lanier, W. L. (2012). Diversion of drugs within health care facilities, a multiple-victim crime: Patterns of diversion, scope, consequences, detection, and prevention. <em>Mayo Clinic Proceedings, 87<\/em>(7), 674\u2013682. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22766087\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22766087<\/a>[\/footnote]<\/sup>\n\nThe DEA provides an online reporting form for individuals to report suspected drug diversion anonymously.<sup> [footnote]U.S. Department of Justice - Drug Enforcement Administration. (n.d.). <a href=\"https:\/\/www.deadiversion.usdoj.gov\/prog_dscrpt\/index.html\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.deadiversion.usdoj.gov\/prog_dscrpt\/index.html<\/a>[\/footnote]<\/sup>\n<div class=\"textbox\">\n<p class=\"arrow\">View the <a href=\"https:\/\/apps2.deadiversion.usdoj.gov\/rxaor\/spring\/main?execution=e2s1\" target=\"_blank\" rel=\"noopener\">RX Abuse Online Reporting form<\/a> to report drug diversion to the DEA.<sup>[footnote]U.S. Department of Justice - Drug Enforcement Administration. (n.d.). <em>RX abuse online reporting: Report incident.<\/em> <a href=\"https:\/\/apps2.deadiversion.usdoj.gov\/rxaor\/spring\/main?execution=e1s1\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/apps2.deadiversion.usdoj.gov\/rxaor\/spring\/main?execution=e1s1<\/a>[\/footnote]<\/sup><\/p>\n\n<\/div>\n<h5>Substance Use Disorder in Health Professionals<\/h5>\nSubstance use disorder (SUD) is an illness caused by repeated misuse of substances such as cannabis, opioids, sedatives, and stimulants. Substances taken in excess have a common effect of directly activating the brain reward system and producing such an intense activation of the reward system that normal life activities may be neglected.<sup>[footnote]American Psychiatric Association. (2013). <em>Desk reference to the diagnostic criteria from DSM-5<\/em>.[\/footnote]<\/sup>\n\nHealth care professionals are not immune to developing SUD. It is important for nurses to be aware of the warning signs of SUD and to understand that SUD is a disease that can affect anyone regardless of age, occupation, economic circumstances, ethnic background, or gender. In most states, a nurse with SUD may voluntarily enter a professional assistance program for evaluation and treatment.<sup>[footnote]National Council of State Boards of Nursing (NCSBN). (2018). <em>A nurse's guide to substance use disorder in nursing.<\/em> <a href=\"https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf<\/a>[\/footnote]<\/sup> Read more about professional assistance programs under the \"State Law, State Nurse Practice Acts, and State Boards of Nursing\" subsection below.\n\nThe National Council of State Boards of Nursing (NCSBN) created <em>A Nurse's Guide to Substance Use Disorder in Nursing<\/em> brochure that states many nurses with substance use disorder (SUD) are unidentified, unreported, untreated, and may continue to practice where their impairment may endanger the lives of their clients or themselves. It can be hard to differentiate between the subtle signs of impairment and stress-related behaviors, but three areas to watch for suspected SUD are behavior changes, physical signs, and drug diversion. Behavioral changes can include changes or shifts in job performance, absences from the unit for extended periods, frequent trips to the bathroom, arriving late or leaving early, and making an excessive number of mistakes, including medication errors. Physical signs include subtle changes in appearance that may escalate over time, increasing isolation from colleagues, inappropriate verbal or emotional responses, and diminished alertness, confusion, or memory lapses. When nurses with SUD commit drug diversion, there are often discrepancies that colleagues notice, such as incorrect opioid counts, a pattern of large amounts of opioid wastage, numerous corrections of medication records, frequent reports of ineffective pain relief from clients assigned to that nurse, increased agitation\/combativeness of assigned clients with dementia, and patterns of increased administration of opioids to clients when that nurse is scheduled to work.<sup>[footnote]National Council of State Boards of Nursing (NCSBN). (2018). <em>A nurse's guide to substance use disorder in nursing.<\/em> <a href=\"https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf<\/a>[\/footnote]<\/sup>\n\nAs a student nurse and nurse, you have a professional and ethical responsibility to report a colleague's suspected SUD to your supervisor and, in some states or jurisdictions, to the State Board of Nursing. The earlier that SUD is identified in a nurse and treatment is started, the sooner clients are protected, and the better the chances for the nurse with SUD to recover and safely return to work.<sup>[footnote]National Council of State Boards of Nursing (NCSBN). (2018). <em>A nurse's guide to substance use disorder in nursing.<\/em> <a href=\"https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf<\/a>[\/footnote]<\/sup>\n<div class=\"textbox\">\n<p class=\"arrow\">Visit the NCSBN's website to read <a href=\"https:\/\/www.ncsbn.org\/nursing-regulation\/practice\/substance-use-disorder\/sud-educational-materials.page\" target=\"_blank\" rel=\"noopener\">\"A Nurse's Guide to Substance Use Disorder in Nursing\"<\/a> brochure.<\/p>\n\n<\/div>\n<h3><a id=\"_lgp5f0df7kyk\" href=\"\"><\/a>Drug Disposal Act<\/h3>\nThe Secure and Responsible Drug Disposal Act of 2010 allows users to dispose of controlled substances in a safe and effective manner. A Johns Hopkins study on sharing of medication found that 60% of people had leftover opioids they saved for future use; 20% shared their medications; 8% would likely share with a friend; 14% would likely share with a relative; and only 10% securely locked their medication.<sup>[footnote]U.S. Department of Justice - Drug Enforcement Administration. (2017, December 13). <em>Federal regulations and the disposal of controlled substances. <\/em><a href=\"https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal<\/a>[\/footnote]<\/sup> This act has resulted in \u201cNational Take Back Days\u201d in all 50 states, as well as new collection receptacles.<sup>[footnote]U.S. Department of Justice - Drug Enforcement Administration. (2017, December 13). <em>Federal regulations and the disposal of controlled substances.<\/em> <a href=\"https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal<\/a>[\/footnote]<\/sup>\n\nTo prevent risk of drug diversion, nurses should teach clients who are prescribed controlled substances how to dispose of them properly so that they don't end up being misused or overdosed by another person. Figure 2.2<sup>[footnote]\u201cMedRx box.JPG\u201d by <a href=\"https:\/\/www.yorkpolice.org\/163\/Town-of-York-Police-Department\" target=\"_blank\" rel=\"noopener noreferrer\">York Police<\/a> is licensed under <a href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/cc0\/\" target=\"_blank\" rel=\"noopener noreferrer\">CC0<\/a>[\/footnote]<\/sup> shows an example of a controlled substances collection receptacle.<sup>[footnote]U.S. Department of Justice - Drug Enforcement Administration. (2017, December 13). <em>Federal regulations and the disposal of controlled substances. <\/em><a href=\"https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal\">https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal<\/a>[\/footnote]<\/sup>\n\n[caption id=\"\" align=\"aligncenter\" width=\"296\"]<img title=\"&quot;MedRx box.JPG&quot; by York Police is licensed under CC0\" src=\"https:\/\/pressbooks.ccconline.org\/accdigitalmarketing\/wp-content\/uploads\/sites\/219\/2025\/01\/image9-2.png\" alt=\"Photograph of a controlled substances collection receptacle\" width=\"296\" height=\"403\"> Figure 2.2 Controlled Substances Collection Receptacle[\/caption]\n\n<div class=\"textbox textbox--examples\"><header class=\"textbox__header\">\n<h2>Critical Thinking Activity 2.3b<img class=\"alignright size-thumbnail wp-image-67\" src=\"https:\/\/pressbooks.ccconline.org\/accdigitalmarketing\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-150x150.png\" alt=\"Image of a circle containing a speech bubble with a question mark in it.\" width=\"150\" height=\"150\"><\/h2>\n<\/header>\n<div class=\"textbox__content\" style=\"text-align: left\">\n<ol>\n \t<li>A nurse is providing discharge education to a client who recently had surgery and has been prescribed hydrocodone\/acetaminophen tablets to take every four hours as needed at home. The nurse explains that when the medication is no longer needed when the post-op pain subsides, it should be dropped off at a local pharmacy for disposal in a collection receptacle. The client states, \u201cI don't like to throw anything away. I usually keep unused medication in case another family member needs it.\u201d\nWhat is the nurse's best response?<\/li>\n \t<li>A nurse begins a new job on a medical-surgical unit. One of the charge nurses on this unit is highly regarded by her colleagues and appears to provide excellent care to her clients. The new nurse cares for a client whom the charge nurse cared for on the previous shift. The new nurse asks the client about the effectiveness of the pain medication documented as provided by the charge nurse during the previous shift. The client states, \u201cI didn't receive any pain medication during the last shift.\u201d The nurse mentions this incident to a preceptor who states, \u201cI have noticed that the same types of incidents have occurred with previous clients but didn't want to say anything.\u201d\nWhat is the new nurse's best response?<\/li>\n<\/ol>\nNote: Answers to the Critical Thinking activities can be found in the \u201c<a href=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/chapter-2\/\" target=\"_blank\" rel=\"noopener\">Answer Key<\/a>\u201d section at the end of the book.\n\n<\/div>\n<\/div>\n<h3><a id=\"_w83njfnfsik1\" href=\"\"><\/a>The Joint Commission<\/h3>\n<strong>[pb_glossary id=\"723\"]The Joint Commission[\/pb_glossary]\u00a0<\/strong>is a national organization that accredits and certifies over 20,000 health care organizations in the United States. The mission of The Joint Commission is to continuously improve health care for the public by inspiring health care organizations to excel in providing safe and effective care of the highest quality and value.<sup>[footnote]The Joint Commission. (n.d.). <a href=\"https:\/\/www.jointcommission.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.jointcommission.org\/<\/a>[\/footnote]<\/sup> Some of The Joint Commission's national initiatives regarding medication safety include creating a \"Safety Culture\" in health care organizations with associated root cause analysis, the Speak Up Campaign, National Patient Safety Goals, and the Official Do not Use List. Each of these safety initiatives is further discussed in the following subsections.\n<h4><a id=\"_p2pv81uos5cy\" href=\"\"><\/a>Safety Culture<\/h4>\nThe Joint Commission Center for Transforming Healthcare develops effective solutions for health care's most critical safety and quality problems with a goal to ultimately achieve zero harm to clients. Some of the projects the Center has developed include improved hand hygiene,<sup>[footnote]Joint Commission Center for Transforming Healthcare. (2020). <em>Hand hygiene.<\/em> <a href=\"https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/hand-hygiene\" target=\"_blank\" rel=\"noopener\">https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/hand-hygiene<\/a>[\/footnote]<\/sup> effective handoff communications,<sup>[footnote]Joint Commission Center for Transforming Healthcare. (2020.) <em>Effective hand-off communications.<\/em> <a href=\"https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/hand-off-communications\" target=\"_blank\" rel=\"noopener\">https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/hand-off-communications<\/a>[\/footnote]<\/sup> and safe and effective use of insulin.<sup>[footnote]Joint Commission Center for Transforming Healthcare. (2020). <em>Safe and effective use of insulin<\/em>. <a href=\"https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/safe-and-effective-use-of-insulin\" target=\"_blank\" rel=\"noopener\">https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/safe-and-effective-use-of-insulin<\/a>[\/footnote] <\/sup>\n\nThe Center has also been instrumental in building a focus on creating a \u201cSafety Culture\u201d in health care organizations. A <strong>[pb_glossary id=\"625\"]Safety Culture[\/pb_glossary]<\/strong> empowers staff to speak up about risks to clients and to report errors and near misses. These actions reduce the risk of client harm. According to the Institute of Medicine, \u201cThe biggest challenge to moving toward a safer health system is changing the culture from one of blaming individuals for errors to one in which errors are treated not as personal failures, but as opportunities to improve the system and prevent harm.\u201d<sup>[footnote]The Joint Commission. (2014, November). <em>Facts about the safety culture project.<\/em> <a href=\"https:\/\/www.centerfortransforminghealthcare.org\/-\/media\/cth\/documents\/improvement-topics\/cth_sc_fact_sheet.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.centerfortransforminghealthcare.org\/-\/media\/cth\/documents\/improvement-topics\/cth_sc_fact_sheet.pdf<\/a>[\/footnote]\u00a0\u00a0<\/sup>\n<div class=\"textbox\">\n<p class=\"arrow\">Visit the <a href=\"https:\/\/www.jointcommission.org\/what-we-offer\/accreditation\/accredited\/accreditation-announcements-and-updates\/safety-culture-assessment-improving-the-survey-process\/\" target=\"_blank\" rel=\"noopener\">Joint Commission's Safety Culture Assessment webpage<\/a> to learn more.<\/p>\n\n<\/div>\nA component of Safety Culture is the submission of incident reports according to agency guidelines whenever a medication error or a \u201cnear miss\u201d occurs. A near miss is a narrowly avoided error. The incident report triggers a <strong>[pb_glossary id=\"548\"]root cause analysis[\/pb_glossary]<\/strong> by the organization to identify not only what and how an event occurred, but also why it happened. When investigators determine why an error occurred, they can create workable corrective measures to prevent future errors from occurring.<sup>[footnote]Patient Safety Network. (2019). <em>Root cause analysis.<\/em> <a href=\"https:\/\/psnet.ahrq.gov\/primer\/root-cause-analysis\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/psnet.ahrq.gov\/primer\/root-cause-analysis<\/a>[\/footnote]<\/sup>\n\nAn example of Safety Culture in action is a tragic event in 2006, when three infants died after incorrect heparin doses were used to flush their vascular access devices. A root cause analysis found that pharmacy technicians accidentally placed vials containing concentrated heparin (10,000 units\/mL) in medication storage locations that were designated for less concentrated heparin vials (10 units\/mL). Additionally, the heparin vials were similar in appearance, so the nurses did not notice the incorrect dosage until after it was administered. In response to a root cause analysis, the hospital no longer stores vials of heparin in pediatric units and uses saline to flush all peripheral lines. In the pharmacy, 10,000 units\/mL heparin vials were separated from vials containing other strengths. In this manner, corrective measures were implemented to prevent future tragedies from occurring as a result of incorrect doses of heparin.<sup>[footnote]Institute for Safe Medication Practices. (2007, November 29). <em>Another heparin error: Learning from mistakes so we don't repeat them.<\/em> <a href=\"https:\/\/www.ismp.org\/resources\/another-heparin-error-learning-mistakes-so-we-dont-repeat-them\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.ismp.org\/resources\/another-heparin-error-learning-mistakes-so-we-dont-repeat-them<\/a>[\/footnote]<\/sup>\n<h4><a id=\"_d1kdgcsew13b\" href=\"\"><\/a>Speak Up Campaign<\/h4>\nThe goal of The Joint Commission's Speak Up\u2122 campaign is to help clients become more informed and involved in their health care to prevent medication errors. Speak Up\u2122 materials are intended for the public and have been put into a simplified, easy-to-read format to reach a wider audience.<sup>[footnote]The Joint Commission. (n.d.). <em>Speak up campaigns. <a href=\"https:\/\/www.jointcommission.org\/resources\/for-consumers\/speak-up-campaigns\/#sort=%40z95xz95xcontentdate%20descending\" target=\"_blank\" rel=\"noopener\">https:\/\/www.jointcommission.org\/resources\/for-consumers\/speak-up-campaigns\/#sort=%40z95xz95xcontentdate%20descending<\/a><\/em>[\/footnote]<\/sup>\n<div class=\"textbox\">\n<p class=\"arrow\">Request additional \"SpeakUp\" materials from <a href=\"https:\/\/www.jointcommission.org\/resources\/news-and-multimedia\/fact-sheets\/facts-about-speak-up\/\" target=\"_blank\" rel=\"noopener\">The Joint Commission Speak Up Fact Sheet webpage<\/a>.<\/p>\n\n<\/div>\n<h4><a id=\"_gdkgehf16byc\" href=\"\"><\/a>National Patient Safety Goals<\/h4>\nThe <strong>[pb_glossary id=\"549\"]National Patient Safety Goals [\/pb_glossary] (NPSG)<\/strong> are established by The Joint Commission to help accredited organizations address current areas of concern related to patient safety. Annually, The Joint Commission determines the current highest priority patient safety issues with input from practitioners, provider organizations, purchasers, consumer groups, and other stakeholders and develops National Patient Safety Goals.\n\nTwo of the current National Patient Safety Goals relate specifically to medication administration: \"Identify Patients Correctly\" and \"Use Medicines Safely.\"\n<div class=\"textbox\">\n<p class=\"arrow\">Review The Joint Commission's <a href=\"https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" target=\"_blank\" rel=\"noopener\">National Patient Safety Goals for Hospitals PDF<\/a><sup>[footnote]The Joint Commission. (2023). <em>2023 hospital national patient safety goals.<\/em> <a href=\"https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf<\/a>[\/footnote]<\/sup><\/p>\n\n<\/div>\n<h5>Identify Patients Correctly<\/h5>\nNurses and health care professionals must use at least two ways to identify clients. For example, use the client's name and date of birth. This is done to make sure that each client gets the correct medicine and treatment.<sup>[footnote]The Joint Commission. (2023). <em>2023 hospital national patient safety goals.<\/em> <a href=\"https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf<\/a>[\/footnote]<\/sup>\n<h5>Use Medicines Safely<\/h5>\nBefore a procedure, label medications that are not labeled. For example, medications in syringes, cups, and basins should be labelled in the area where medications and supplies are set up. Labels should include medication name, dose, date drawn up, and initials of the person who prepared the medication.<sup>[footnote]The Joint Commission. (2023). <em>2023 hospital national patient safety goals<\/em>. <a href=\"https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf<\/a>[\/footnote]<\/sup> Additionally, do not leave medications unattended.\n\nRecord and pass along correct information about a client's medications. Find out what medications the client is taking. Compare those medications to new medications given to the client. Make sure the client knows which medications to take when they are at home. Tell the client it is important to bring their up-to-date list of medications every time they visit a doctor. Extra care must be taken with clients who take medications to thin their blood (anticoagulants).<sup>[footnote]The Joint Commission. (2023). <em>2023 hospital national patient safety goals<\/em>. <a href=\"https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf<\/a>[\/footnote]<\/sup>\n<h4><a id=\"_xgxlubfdu0h2\" href=\"\"><\/a>The Joint Commission's Official Do Not Use List<\/h4>\nThe Joint Commission maintains an Official Do Not Use List of abbreviations. These abbreviations have been found to commonly cause errors in client care. Accredited agencies are expected to not use these abbreviations on any written or preprinted materials.<sup>[footnote]The Joint Commission. (2023). <em>Do not use list fact sheet.<\/em> <a href=\"https:\/\/www.jointcommission.org\/facts_about_do_not_use_list\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.jointcommission.org\/facts_about_do_not_use_list\/<\/a>[\/footnote]<\/sup>\n<div class=\"textbox\">\n<p class=\"arrow\">Read The Joint Commission's\u00a0 <a href=\"https:\/\/www.jointcommission.org\/resources\/news-and-multimedia\/fact-sheets\/facts-about-do-not-use-list\/\" target=\"_blank\" rel=\"noopener\">Official Do Not Use List Fact Sheet<\/a><\/p>\n\n<\/div>\n<h3>CMS: Centers for Medicare and Medicaid Services<\/h3>\nThe Centers for Medicare &amp; Medicaid Services (CMS) is a federal agency within the United States Department of Health and Human Services (HHS). The CMS administers the Medicare program and works in partnership with state governments to administer Medicaid and establishes and enforces regulations to protect client safety in hospitals that receive Medicare and Medicaid funding.<sup>[footnote]U.S. Department of Health &amp; Human Services, Centers for Medicare &amp; Medicaid Services. (2014). <em>Memo: Requirements for hospital medication administration, particularly intravenous (IV) medications and post-operative care of patients receiving IV opioids<\/em>. <a href=\"https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf<\/a>[\/footnote]<\/sup>\n\nCMS regulations related to the administration of medication by nurses include verifying information included in the prescription for a medication, checking the rights of medication administration, reporting concerns about a medication prescription, assessing and monitoring clients receiving medications, and documenting medication administration. Each of these regulations is further discussed below.\n<h4><a id=\"_d8fnzu4041iw\" href=\"\"><\/a>Verifying Prescriptions<\/h4>\nMedications and biologicals are administered in response to a prescription from a health care provider or on the basis of a standing order that is subsequently authenticated by a provider. Biologicals are a diverse group of medications that include vaccines, growth factors, immune modulators, monoclonal antibodies, and products derived from blood and plasma. All provider orders for the administration of drugs and biologicals must include the following:\n<ul>\n \t<li>Name of the client<\/li>\n \t<li>Age and weight of the client to facilitate dose calculation when applicable. Agency policies and procedures must address weight-based dosing for pediatric client. Dose calculations for newborns are typically based on the metric weight in grams.<\/li>\n \t<li>Date and time of the order<\/li>\n \t<li>Drug name<\/li>\n \t<li>Dose, frequency, and route<\/li>\n \t<li>Dose calculation requirements, when applicable<\/li>\n \t<li>Exact strength or concentration, when applicable<\/li>\n \t<li>Quantity and\/or duration, when applicable<\/li>\n \t<li>Specific instructions for use, when applicable<\/li>\n \t<li>Name of the provider<\/li>\n<\/ul>\n<h4><a id=\"_bbpddzg21jjr\" href=\"\"><\/a>Checking The Rights of Medication Administration<\/h4>\nThe CMS states that agency policies and procedures must reflect accepted standards of practice that require specific information is confirmed prior to administration of medication. This is commonly referred to as \"checking the rights of medication administration.\"\n\nWhen administering medications, it is essential for nurses to vigilantly check the rights of medication administration at least three times to prevent medication errors. What historically began as checking five rights of mediation administration has been extended to eight rights according to the American Nurses Association. These eight rights include the following<sup>[footnote]American Nurses Association. (2021). <em>ANA issue brief: Use of medication assistants\/aides\/technicians.<\/em> <a href=\"https:\/\/www.nursingworld.org\/~498e32\/contentassets\/a2ff1bd2d5ca467699c3bc764f7d9198\/issue-brief-medication-aides-4-2021.docx\" target=\"_blank\" rel=\"noopener\">https:\/\/www.nursingworld.org\/~498e32\/contentassets\/a2ff1bd2d5ca467699c3bc764f7d9198\/issue-brief-medication-aides-4-2021.docx<\/a>[\/footnote]<\/sup>:\n<ul>\n \t<li><strong>Right patient:<\/strong> Check that you have the correct client using two patient identifiers according to agency policy (e.g., name and date of birth).<\/li>\n \t<li style=\"font-weight: 400\"><strong>Right medication:<\/strong> Check that you have the correct medication and that it is appropriate for the patent in the current context. Understand the purpose of the medication and why the client is receiving it.<\/li>\n \t<li style=\"font-weight: 400\"><strong>Right dose:<\/strong> Check that the dose is safe for the age, size, and condition of the client. Different dosages may be indicated for different conditions, and pediatric dosages are typically much lower than adult dosages.<\/li>\n \t<li style=\"font-weight: 400\"><strong>Right route:<\/strong> Check that the route is appropriate for the client\u2019s current condition.<\/li>\n \t<li style=\"font-weight: 400\"><strong>Right time:<\/strong> Adhere to the prescribed scheduling of the medication.<\/li>\n \t<li style=\"font-weight: 400\"><strong>Right documentation:<\/strong> Always verify any unclear or inaccurate documentation prior to administering medications.<\/li>\n \t<li><strong>Right reason:<\/strong> Verify this medication is being administered to this client at this time for the right reason. If signs and symptoms no longer warrant administration of the prescribed medication, notify the prescribing provider.<\/li>\n \t<li><strong>Right response: <\/strong>After administering medication, the nurse must evaluate for expected outcomes with the time frame of expected onset and peak. The onset of medication administration occurs when the action of the medication begins to take effect. The peak of the medication administration occurs when the medication is at the highest level in the client\u2019s bloodstream. It is important for nurses to be aware of both the peak and onset of medications to know when the client's response to medication may start to be observed. The nurse must also be aware of potential side effects and adverse effects and evaluate for these unexpected outcomes. The prescribing provider should be notified if expected outcomes are not achieved or if adverse effects occur.<\/li>\n<\/ul>\nMany agencies have implemented barcode medication scanning to improve safety during medication administration. Barcode scanning systems reduce medication errors by electronically verifying the \u201crights\u201d of medication administration. For example, when a nurse scans a barcode on the client's wristband and on the medication to be administered, the data is delivered to a computer software system where algorithms check databases and generate real-time warnings or approvals. Barcode scanning reduces errors resulting from administration of a wrong medication, incorrect dose, or wrong route. However, it is important for nurses to remember that barcode scanning should be used in addition to checking the rights of medication administration, not in place of this important safety process. Additionally, nurses should carefully consider their actions when errors occur during the barcode scanning process. Although it may be tempting to quickly dismiss the error and attribute it to a technology glitch, the error may have been triggered due to a patient safety concern that requires further follow-up before the medication is administered. Nurses must investigate errors that occur during the barcode scanning process just as they would do if an error were discovered while checking the rights of medication administration.\n<div class=\"textbox \">\n<p class=\"video\">View a supplementary YouTube video<sup>[footnote]Kimberly Dunker. (2020, April 6). <em>Mediation Administration. <\/em>[Video]. YouTube. All rights reserved. <a href=\"https:\/\/youtu.be\/MUn4Ec2X93g\" target=\"_blank\" rel=\"noopener\">https:\/\/youtu.be\/MUn4Ec2X93g<\/a>[\/footnote]<\/sup> example of a student preparing to administer medication and checking the rights of medication administration: <a href=\"https:\/\/youtu.be\/MUn4Ec2X93g\" target=\"_blank\" rel=\"noopener\">Medication Administration.<\/a><\/p>\n\n<\/div>\n<h4><a id=\"_4sfkusc12i7o\" href=\"\"><\/a>Communicating Concerns About Medication Orders<\/h4>\nThe CMS encourages hospitals to promote a culture in which it is not only acceptable, but also strongly encouraged, for staff to notify prescribing providers regarding concerns they have regarding medication orders.<sup>[footnote]U.S. Department of Health &amp; Human Services, Centers for Medicare &amp; Medicaid Services. (2014). <em>Memo: Requirements for hospital medication administration, particularly intravenous (IV) medications and post-operative care of patients receiving IV opioids<\/em>. <a href=\"https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf<\/a>[\/footnote]<\/sup> It is essential for nurses to contact the prescribing provider if they have any concerns when checking the rights of medication administration before administering the medication to the client. Furthermore, nurses can be held liable in a court of law if they administer medication that results in client harm if a \"prudent nurse\" would have had concerns about the order and questioned it.\n<h4><a id=\"_gdcisn9j8vzp\" href=\"\"><\/a>Monitoring Clients Receiving Medications<\/h4>\nThe CMS states that observing the effects medications have on the client is part of the multifaceted medication administration process. Clients must be carefully monitored to determine whether the medication results in the therapeutically intended benefit and to allow for early identification of adverse effects and timely initiation of appropriate corrective action. Depending on the medication and route\/delivery mode, monitoring may include assessment of the following:\n<ul>\n \t<li>Clinical and laboratory data to evaluate the efficacy of medication therapy, potential toxicity, and adverse effects. For some medications, such as opioids, this monitoring may include clinical data such as respiratory status, blood pressure, and oxygenation and carbon dioxide levels.<\/li>\n \t<li>Physical signs and clinical symptoms relevant to the client's medication therapy, such as confusion, agitation, unsteady gait, pruritus, etc.<\/li>\n \t<li>Factors contributing to high risk for adverse drug events. The consequences of errors can be harmful and sometimes fatal to clients. In addition, certain factors place some clients at greater risk for adverse effects of medication. These factors include, but are not limited to, age, altered liver and kidney function, drug-to-drug interactions, and first-time medication use.<\/li>\n<\/ul>\nThe nurse should consider client risk factors, as well as the risks inherent in a medication, when determining the type and frequency of monitoring. It is also essential to communicate information regarding client medication risk factors and monitoring requirements during hand-off reports to other staff.\n\nAdverse client reactions, such as anaphylaxis or opioid-induced sedation and respiratory depression, require timely and appropriate intervention per agency protocols and should also be immediately reported to the prescribing provider. An example of vigilant post-medication administration monitoring is when a nurse closely monitors a post-surgical client who is receiving opioid pain medication via a patient-controlled analgesia (PCA) pump. Opioid medications are used to control pain but also have a sedating effect. Clients can become overly sedated and suffer respiratory depression or arrest, which can be fatal. The nurse should closely monitor the client's respiratory rate, oxygen saturation, carbon dioxide levels, level of sedation, blood pressure, and pulse to quickly observe and intervene in the event of an adverse event. In addition, the client and\/or family members are educated to notify nursing staff promptly when there is difficulty breathing or other changes that might be a reaction to medication.<sup>[footnote]U.S. Department of Health &amp; Human Services, Centers for Medicare &amp; Medicaid Services. (2014). <em>Memo: Requirements for hospital medication administration, particularly intravenous (IV) medications and post-operative care of patients receiving IV opioids<\/em>. <a href=\"https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf<\/a>[\/footnote]<\/sup>\n<h4><a id=\"_lq4z5pjwif5d\" href=\"\"><\/a>Documenting<\/h4>\nCMS regulations require the agency's documentation regarding medication administration contains providers' orders, nursing notes, reports of treatment, medication administration records, radiology and laboratory reports, vital signs, and other information necessary to monitor the client's condition. Documentation of medication administration is expected to occur immediately after the medication is administered to the client; documenting prior to the administration of the medication is inappropriate and can result in medication errors. Proper documentation of medication administration and client outcomes is essential for planning and delivering future care of the client.<sup>[footnote]U.S. Department of Health &amp; Human Services, Centers for Medicare &amp; Medicaid Services. (2014). <em>Memo: Requirements for hospital medication administration, particularly intravenous (IV) medications and post-operative care of patients receiving IV opioids<\/em>. <a href=\"https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf<\/a>[\/footnote],[footnote]American Society of Health-System Pharmacists (Ed.). (2018). ASHP guidelines on preventing medication errors in hospitals. <em>American Journal of Health-System Pharmacy, 75<\/em>, 1493\u20131517. <a href=\"https:\/\/www.ashp.org\/-\/media\/assets\/policy-guidelines\/docs\/guidelines\/preventing-medication-errors-hospitals.ashx\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.ashp.org\/-\/media\/assets\/policy-guidelines\/docs\/guidelines\/preventing-medication-errors-hospitals.ashx<\/a> [\/footnote]<\/sup>\n<div class=\"__UNKNOWN__\">\n<div class=\"textbox textbox--examples\"><header class=\"textbox__header\">\n<h2>Critical Thinking Activity 2.3c<img class=\"alignright size-thumbnail wp-image-67\" src=\"https:\/\/pressbooks.ccconline.org\/accdigitalmarketing\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-150x150.png\" alt=\"Image of a circle containing a speech bubble with a question mark in it.\" width=\"150\" height=\"150\"><\/h2>\n<\/header>\n<div class=\"textbox__content\" style=\"text-align: left\">\n\nA nurse is preparing to administer morphine, an opioid, to a client who recently had surgery.\n<ol>\n \t<li>Explain the rights of medication administration the nurse must check prior to administering this medication to the client.<\/li>\n \t<li>Outline three methods the nurse can use to confirm patient identification.<\/li>\n \t<li>What should the nurse assess prior to administering this medication to the client?<\/li>\n \t<li>What should be monitored after administering this medication?<\/li>\n \t<li>What should the nurse teach the client (and\/or family member) about this medication?<\/li>\n \t<li>What information should be included in the shift handoff report about this medication?<\/li>\n<\/ol>\nNote: Answers to the Critical Thinking activities can be found in the \u201c<a href=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/chapter-2\/\" target=\"_blank\" rel=\"noopener\">Answer Key<\/a>\u201d section at the end of the book.\n\n<\/div>\n<\/div>\n<\/div>\n<h2><a id=\"_i8t0mz3k0qmj\" href=\"\"><\/a>State Law, State Nurse Practice Acts, and State Boards of Nursing<\/h2>\nIn additional to federal laws, regulations, national guidelines, and safety initiatives, state law also protects public health and safety. Each state has a Nurse Practice Act (NPA) that is enacted by the state legislature. The State Board of Nursing (SBON) enforces the NPA.<sup>[footnote]Wisconsin Department of Safety and Professional Services. (n.d.). <em>Wisconsin nurse practice act (NPA) course.<\/em> <a href=\"https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf<\/a>[\/footnote]<\/sup> The purpose of the SBON is to protect the public through licensure, education, legislation, and discipline regarding rules of conduct. The SBON regulates the licensure and practice of registered nurses (RNs), licensed practical\/vocational nurses (LPNs\/VNs), and advanced practice nurse prescribers (APNPs).<sup>[footnote]Wisconsin Department of Safety and Professional Services. (n.d.). <em>Wisconsin nurse practice act (NPA) course.<\/em> <a href=\"https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf<\/a>[\/footnote]<\/sup>\n\nNurses are responsible for knowing the state laws that relate to nursing care in the state in which they work. Furthermore, nurses must follow the scope of practice outlined in the NPA in the state in which they are employed. Nurses are accountable for the quality of care they provide and are expected to practice at the level of education, knowledge, and skill of someone who has completed an approved nursing program. All nurses are expected to recognize the limits of their knowledge and experience and to appropriately address situations that are beyond their competency.<sup>[footnote]Wisconsin Department of Safety and Professional Services. (n.d.). <em>Wisconsin nurse practice act (NPA) course.<\/em> <a href=\"https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf<\/a>[\/footnote]<\/sup>\n<div class=\"textbox\">\n<p class=\"arrow\">See an <a href=\"https:\/\/dsps.wi.gov\/Pages\/RulesStatutes\/Nursing.aspx\" target=\"_blank\" rel=\"noopener\">example of a Nurse Practice Act<\/a> established by the Wisconsin Board of Nursing.<sup><a class=\"rId37\" href=\"https:\/\/dsps.wi.gov\/Pages\/RulesStatutes\/Nursing.aspx\">[footnote]<\/a>Wisconsin Department of Safety and Professional Services. (n.d.). <em>Board of nursing Wisconsin Administrative Code.<\/em>\u00a0<a class=\"rId37\" href=\"https:\/\/dsps.wi.gov\/Pages\/RulesStatutes\/Nursing.aspx\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Pages\/RulesStatutes\/Nursing.aspx[\/footnote]<\/a><\/sup><\/p>\n\n<\/div>\n<h3>Nurse<a id=\"_3apvx8llmlxh\" href=\"\"><\/a>\u00a0Practice Act: Standards of Practice<\/h3>\nThe NPA outlines the standards of care provided by a registered nurse (RN), also known as the <strong>[pb_glossary id=\"626\"]nursing process[\/pb_glossary]<\/strong>. As previously discussed in this chapter, the steps of the nursing process are also considered a standard of care by the ANA. A nurse utilizes the nursing process when executing nursing care and procedures in the maintenance of clients' health, prevention of illness, or care of the ill. Review the steps of the nursing process in the \"<a href=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/2-2-ethical-and-professional-foundations-of-safe-medication-administration-by-nurses\/\" target=\"_blank\" rel=\"noopener\">Ethical and Professional Foundations of Safe Medication Administration by Nurses<\/a>\" section of this chapter.\n<h3><a id=\"_cmg8l16gvfj9\" href=\"\"><\/a>Nurse Practice Act: Rules of Conduct<\/h3>\nThe NPA also outlines rules of conduct expected of nurses. Nurses can receive disciplinary action from the SBON, ranging from a reprimand to revocation of their license, if they do not follow the enacted rules of conduct. A nurse must maintain current knowledge about expected rules of conduct in each state where they practice nursing to protect their nursing license.\n<div class=\"textbox\">\n<p class=\"arrow\">View an example of Rules of Conduct established in Chapter N7, <a href=\"https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/n\/7.pdf\" target=\"_blank\" rel=\"noopener\">\"Rules of Conduct,\" of the Wisconsin Nurse Practice Act PDF<\/a>.<sup>[footnote]Wisconsin Department of Safety and Professional Services. (n.d.). <em>Wisconsin nurse practice act (NPA) course.<\/em> <a href=\"https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf<\/a>[\/footnote],[footnote]Wisconsin State Legislature. (2016, August). <em>Chapter N7 rules of conduct. <\/em><a href=\"https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/n\/7.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/n\/7.pdf<\/a>[\/footnote]<\/sup><\/p>\n\n<\/div>\nA SBON may take disciplinary action against a nurse's license for many reasons. Common reasons related to medication administration include, but are not limited to, the following:\n<ul>\n \t<li>Noncompliance with federal, jurisdictional, or reporting requirements, including practicing beyond the scope of practice.<\/li>\n \t<li>Confidentiality, client privacy, consent, or disclosure violations.<\/li>\n \t<li>Fraud, deception or misrepresentation, including falsification of client documentation.<\/li>\n \t<li>Unsafe practice or substandard care, including:\n<ul>\n \t<li>Failing to perform nursing care with reasonable skill and safety.<\/li>\n \t<li>Departing from or failing to conform to the minimal standards of acceptable nursing practice that may create unnecessary risk or danger to a client's life, health, or safety. Actual injury to a client does not need to be established.<\/li>\n \t<li>Failing to report to or leaving a nursing assignment without properly notifying appropriate supervisory personnel and ensuring the safety and welfare of the client.<\/li>\n \t<li>Practicing nursing while under the influence of alcohol, illicit drugs, or while impaired by the use of legitimately prescribed pharmacological agents or medications.<\/li>\n \t<li>Inability to practice safely due to alcohol or other substance use, psychological or physical illness, or impairment.<\/li>\n \t<li>Executing an order which the licensee knew or should have known could harm a client.<\/li>\n<\/ul>\n<\/li>\n \t<li>Improper supervision.<\/li>\n \t<li>Improper prescribing, dispensing, or administering medication or drug-related offenses.<sup>[footnote]Wisconsin Department of Safety and Professional Services. (n.d.). <em>Wisconsin nurse practice act (NPA) course.<\/em> <a href=\"https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf<\/a>[\/footnote]<\/sup><\/li>\n<\/ul>\n<h3><a id=\"_m6j5wqv1r3pq\" href=\"\"><\/a>State Statutes Related to Controlled Substances<\/h3>\n<a id=\"_2dtqojbdakka\" href=\"\"><\/a>In addition to the NPA, there are other state statutes that guide nursing care and medication administration. State statutes are a compilation of the general laws of the state and often include chapters related to the state regulation of controlled substances (in addition to federal law previously discussed in this section).\n<div class=\"textbox\">\n<p class=\"arrow\">View an <a href=\"https:\/\/docs.legis.wisconsin.gov\/statutes\/statutes\/961\" target=\"_blank\" rel=\"noopener\">example of state regulation of controlled substances<\/a> in Wisconsin Chapter 961: Uniform Controlled Substances Act.<\/p>\n\n<\/div>\n<h4><a id=\"_vx88vyc3zvqo\" href=\"\"><\/a>Prescription Drug Monitoring Program<\/h4>\nExamples of state law related to controlled substances are prescription drug monitoring programs (PDMP). Many states have implemented PDMP to help combat the ongoing prescription substance abuse epidemic, as well as to help prevent drug diversion. Pharmacies and health care providers are often required by state law to participate in a PDMP when dispensing or prescribing controlled substances. A PDMP is a statewide electronic database that collects data on substances dispensed in the state. By providing valuable information about controlled substance prescriptions that are dispensed in the state, PDMPs help health care providers make prescribing and dispensing decisions. PDMPs also foster the ability of pharmacies, health care professionals, law enforcement agencies, and public health officials to work together to reduce the misuse, abuse, and diversion of prescribed controlled substances.\n<div class=\"textbox\">\n<p class=\"arrow\">View <a href=\"https:\/\/pdmp.wi.gov\" target=\"_blank\" rel=\"noopener\">Wisconsin's Enhanced Prescription Drug Monitoring Program (ePDMP)<\/a><sup>[footnote]Wisconsin ePDMP. (2019). <a href=\"https:\/\/pdmp.wi.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/pdmp.wi.gov\/<\/a>[\/footnote]<\/sup><\/p>\n\n<\/div>\n<h4><a id=\"_cpals5n9c270\" href=\"\"><\/a>Professional Assistance Programs<\/h4>\nIn addition to state statutes related to controlled substances, many states offer professional assistance programs as voluntary, nondisciplinary programs to provide support for health professionals with substance abuse disorders (SUD) who are committed to their own recovery. The goal of professional assistance programs is to protect the public by promoting early identification of professionals with SUD and encouraging their rehabilitation and recovery. Professional assistance programs provide an opportunity for nurses with SUD to continue to be employed while being monitored by the SBON and supported in their recovery.\n<div class=\"textbox\">\n<p class=\"arrow\">View <a href=\"https:\/\/pdmp.wi.gov\" target=\"_blank\" rel=\"noopener\">Wisconsin's Professional Assistance Program<\/a>.<sup>[footnote]Wisconsin Department of Safety and Professional Services. (n.d.). <em>Wisconsin nurse practice act (NPA) course.<\/em> <a href=\"https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf<\/a>[\/footnote]\u00a0<\/sup><\/p>\n\n<\/div>\n<div class=\"__UNKNOWN__\">\n<div class=\"textbox textbox--examples\"><header class=\"textbox__header\">\n<h2>Critical Thinking Activity 2.3d<img class=\"alignright size-thumbnail wp-image-67\" src=\"https:\/\/pressbooks.ccconline.org\/accdigitalmarketing\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-150x150.png\" alt=\"Image of a circle containing a speech bubble with a question mark in it.\" width=\"150\" height=\"150\"><\/h2>\n<\/header>\n<div class=\"textbox__content\" style=\"text-align: left\">\n\nA nurse is disciplined by the Wisconsin Board of Nursing for an incident reported by her employer that she arrived at her shift intoxicated. The nurse shares with a nursing colleague, \u201cI love taking care of patients. I worked so hard to obtain my nursing license - I don't want to lose it. I know my drinking has gotten out of control, but I don't know where to turn.\u201d\n\nWhat is the best advice by the nursing colleague for this nurse with a drinking problem?\n\nNote: Answers to the Critical Thinking activities can be found in the \u201c<a href=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/chapter-2\/\" target=\"_blank\" rel=\"noopener\">Answer Key<\/a>\u201d section at the end of the book.\n\n<\/div>\n<\/div>\n<\/div>","rendered":"<p>Many federal and state laws, as well as national guidelines, have been established to protect public health and safety related to medication administration. This section will explain how federal and state laws, agencies, and guidelines protect clients from harm from medications.<\/p>\n<h2>Federal Agencies, Laws, and Guidelines<\/h2>\n<h3>Food and Drug Administration<\/h3>\n<p>The United States Food and Drug Administration (FDA) protects public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices, as well as the safety of our nation&#8217;s food supply, cosmetics, and products that emit radiation.<sup><a class=\"footnote\" title=\"U.S. Food and Drug Administration. (n.d). https:\/\/www.fda.gov\" id=\"return-footnote-69-1\" href=\"#footnote-69-1\" aria-label=\"Footnote 1\"><sup class=\"footnote\">[1]<\/sup><\/a><\/sup> The FDA protects public health by enforcing an official drug approval process based on evidence-based research and issuing Boxed Warnings for medications with serious adverse reactions. These actions are further discussed in the following subsections.<\/p>\n<h4><a id=\"_3mwn8iw3zliz\" href=\"\"><\/a>Developing New Drugs<\/h4>\n<p>American consumers benefit from having access to the safest and most advanced pharmaceutical system in the world. The main consumer watchdog in this system is the FDA&#8217;s Center for Drug Evaluation and Research (CDER). The center&#8217;s best-known job is to evaluate new drugs before they can be sold. CDER&#8217;s evaluation not only prevents misinformation from being provided to the public, but also provides doctors and clients the information they need to use medicines wisely. CDER ensures that drugs, both brand-name and generic, work correctly and their health benefits outweigh their known risks.<\/p>\n<p>Drug companies conduct extensive research and work to develop and test a drug. The company then sends CDER the evidence from these tests to prove the drug is safe and effective for its intended use. Before the drug is approved as safe for use in the United States, a team of CDER physicians, statisticians, chemists, pharmacologists, and other scientists reviews the company&#8217;s data and proposed labeling. If this independent and unbiased review establishes a drug&#8217;s health benefits outweigh its known risks, the drug is approved for sale. Before a drug can be tested in people, the drug company or sponsor performs laboratory and animal tests to discover how the drug works and whether it&#8217;s likely to be safe and work well in humans. Next, a series of clinical trials involving volunteers is conducted to determine whether the drug is safe when used to treat a disease and whether it provides a real health benefit.<\/p>\n<div class=\"textbox\">\n<p class=\"arrow\">Visit the FDA&#8217;s &#8220;<a href=\"https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\" target=\"_blank\" rel=\"noopener\">Development and Approval Process | Drugs&#8221; webpage<\/a>.<\/p>\n<\/div>\n<h4><a id=\"_id4s01tcl6zm\" href=\"\"><\/a>FDA Approval of a Drug<\/h4>\n<p>FDA approval of a drug means that data on the drug&#8217;s effects have been reviewed by the CDER, and the drug is determined to provide benefits that outweigh its known and potential risks for the intended population. The drug approval process takes place within a structured framework that includes the following:<\/p>\n<ul>\n<li><strong>Analysis of the target condition and available treatments:<\/strong> FDA reviewers analyze the condition or illness for which the drug is intended and evaluate the current treatment landscape, which provide the context for weighing the drug&#8217;s risks and benefits. For example, a drug intended to treat clients with a life-threatening disease for which no other therapy exists may be considered to have benefits that outweigh the risks even if those risks would be considered unacceptable for a condition that is not life-threatening.<\/li>\n<li><strong>Assessment of benefits and risks from clinical data:<\/strong> FDA reviewers evaluate clinical benefit and risk information submitted by the drug maker, taking into account any uncertainties that may result from imperfect or incomplete data. Generally, the agency expects that the drug maker will submit results from two well-designed clinical trials to be sure the findings from the first trial are not the result of chance or bias. In certain cases, especially if the disease is rare and multiple trials may not be feasible, convincing evidence from one clinical trial may be enough. Evidence that the drug will benefit the target population should outweigh any risks and uncertainties.<\/li>\n<li><strong>Strategies for managing risks:<\/strong> All drugs have risks. Risk management strategies include an FDA-approved drug label, which clearly describes the drug&#8217;s benefits and risks and information pertaining to the detection and management of any risks. Sometimes, more effort is needed to manage risks. In these cases, a drug maker may need to implement a Risk Evaluation and Mitigation Strategy (REMS).<\/li>\n<\/ul>\n<p>Although many of the FDA&#8217;s risk-benefit assessments and decisions are straightforward, sometimes the benefits and risks are uncertain and may be difficult to interpret or predict. The agency and the drug maker may reach different conclusions after analyzing the same data, or there may be differences of opinion among members of the FDA&#8217;s review team. As a science-led organization, the FDA uses scientific and technological information to make decisions through a deliberative process.<sup><a class=\"footnote\" title=\"U.S. Food and Drug Administration. (n.d.). Developing new drugs. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\" id=\"return-footnote-69-2\" href=\"#footnote-69-2\" aria-label=\"Footnote 2\"><sup class=\"footnote\">[2]<\/sup><\/a><\/sup><\/p>\n<h4><a id=\"_t0376x72b8jl\" href=\"\"><\/a>Boxed Warnings<\/h4>\n<p>As discussed in the previous subsection, the FDA approves a drug after determining that the drug&#8217;s benefits of use outweigh the risks for the condition that the drug will treat. However, even with the rigorous FDA evaluation process, safety problems can surface after a drug has been on the market and used in a broader population.<\/p>\n<p><strong><a class=\"glossary-term\" aria-haspopup=\"dialog\" aria-describedby=\"definition\" href=\"#term_69_623\">Boxed Warnings<\/a><\/strong> (formerly known as Black Box Warnings) are the highest safety-related warning that medications can have assigned by the FDA. These warnings are intended to bring the consumer\u2019s attention to the major risks of the drug. Medications can have a boxed warning added, taken away, or updated throughout their tenure on the market. Boxed Warnings appear on a prescription drug&#8217;s label and in current, evidence-based drug references. For this reason, it is important for nurses to verify current drug information in drug references.<\/p>\n<div class=\"textbox textbox--examples\">\n<header class=\"textbox__header\">\n<h2><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-67 size-thumbnail\" src=\"https:\/\/pressbooks.ccconline.org\/accdigitalmarketing\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-150x150.png\" alt=\"Image of a circle containing a speech bubble with a question mark in it.\" width=\"150\" height=\"150\" srcset=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-150x150.png 150w, https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-65x65.png 65w, https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-225x225.png 225w, https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1.png 300w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/>Critical Thinking Activity 2.3a<\/h2>\n<\/header>\n<div class=\"textbox__content\">\n<p>Levofloxacin is an antibiotic that received FDA approval. However, after the drug was on the market, it was discovered that some clients who took levofloxacin developed serious, irreversible adverse effects such as tendon rupture. The FDA issued a Boxed Warning with recommendations to reserve levofloxacin for use in clients who have no alternative treatment options for certain indications: uncomplicated UTI, acute exacerbation of chronic bronchitis, and acute bacterial sinusitis.<sup><a class=\"footnote\" title=\"This work is a derivative of DailyMed by U.S. National Library of Medicine in the Public Domain.\" id=\"return-footnote-69-3\" href=\"#footnote-69-3\" aria-label=\"Footnote 3\"><sup class=\"footnote\">[3]<\/sup><\/a><\/sup><\/p>\n<p>A nurse is preparing to administer medications to a client and notices that levofloxacin has been prescribed for the indication of pneumonia. There is no other documentation in the provider&#8217;s notes related to the use of this medication.<\/p>\n<p>What is the nurse&#8217;s best response?<\/p>\n<p>Note: Answers to the Critical Thinking activities can be found in the \u201c<a href=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/chapter-2\/\" target=\"_blank\" rel=\"noopener\">Answer Key<\/a>\u201d section at the end of the book.<\/p>\n<\/div>\n<\/div>\n<h3>U.S. Drug Enforcement Agency (DEA)<\/h3>\n<p>The U.S. Drug Enforcement Agency (DEA) enforces the federal laws and regulations of controlled substances. This includes enforcement of the Controlled Substances Act (CSA) that pertains to the manufacture, distribution, and dispensing of legally produced controlled substances that nurses administer to clients.<sup><a class=\"footnote\" title=\"U.S. Department of Justice - Drug Enforcement Administration. (n.d.). Drug scheduling. https:\/\/www.dea.gov\/drug-scheduling\" id=\"return-footnote-69-4\" href=\"#footnote-69-4\" aria-label=\"Footnote 4\"><sup class=\"footnote\">[4]<\/sup><\/a><\/sup><\/p>\n<p>Because controlled substances have a greater chance of being misused and abused, there are additional laws and procedures that must be followed when working with these medications. The DEA is responsible for enforcing these laws, and many federal laws are summarized in a document called the <em>Pharmacist&#8217;s Manual<\/em>. Most controlled substance laws, however, come from state governments. Health care professionals are responsible for following the most stringent of the two laws, whether it be state law or federal law.<\/p>\n<div class=\"textbox\">\n<p class=\"arrow\">View the DEA&#8217;s <a href=\"https:\/\/www.deadiversion.usdoj.gov\/GDP\/%28DEA-DC-046R1%29%28EO-DEA154R1%29_Pharmacist%27s_Manual_DEA.pdf\" target=\"_blank\" rel=\"noopener\">Pharmacist&#8217;s Manual<\/a> PDF.<\/p>\n<\/div>\n<h4>Examples of Federal and State Laws Regarding Controlled Substances<\/h4>\n<p>The following examples of federal laws are applicable to controlled substances administered by nurses:<\/p>\n<ul>\n<li><strong>Prescriptions:<\/strong> A prescription for a controlled substance may be written only by a provider (physician or mid-level provider such as a nurse practitioner) who has a DEA registration number. The prescription for a Schedule II medication (i.e., opioids) must be written or electronically sent to the pharmacy through DEA approved software. Prescriptions over the phone or fax are not accepted. Refills for Schedule II medication are not allowed and require new prescriptions. Schedule III or IV medications may be refilled only five times. State law determines how long a written Schedule II prescription is valid and if there are any limits on the quantity of medication that can be dispensed. For example, in Wisconsin, a Schedule II prescription is only valid for 60 days after it is written.<\/li>\n<li><strong>Records:<\/strong> There is a \u201cclosed system\u201d for record keeping of controlled substances to prevent drug diversion. Hospitals, clinics, and pharmacies must maintain records on the whereabouts of controlled substances from the time the medication is received by the pharmacy, to when it is administered to the client, to disposal of wasted medication by the nurse. Inventory counts of controlled substances occur frequently and may require a physical count by two licensed staff at the start of each shift. Detailed documentation is required for administration of controlled substances. When a full dose of a controlled substance is not administered, this is referred to as waste. Waste is typically disposed of differently than other medications (i.e., flushed down the sink) and often requires the co-signature of a second licensed staff member.<\/li>\n<\/ul>\n<div class=\"textbox\">\n<p class=\"arrow\">View the\u00a0<a href=\"https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/phar\/8.pdf\" target=\"_blank\" rel=\"noopener\">Requirements for Controlled Substances PDF<\/a><span style=\"font-size: 12.8px\"><a class=\"footnote\" title=\"Wisconsin Administrative Code. (2022).\u00a0Uniform Controlled Substances Act.\u00a0https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/phar\/8.pdf\" id=\"return-footnote-69-5\" href=\"#footnote-69-5\" aria-label=\"Footnote 5\"><sup class=\"footnote\">[5]<\/sup><\/a><\/span> with additional information about Wisconsin state laws regarding controlled substances.<\/p>\n<\/div>\n<h4><a id=\"_tj7fz92l0928\" href=\"\"><\/a>Schedules of Drugs<\/h4>\n<p>The federal Controlled Substances Act (CSA) categorizes drugs regulated under federal law into one of five schedules. This placement is based on the substance&#8217;s medical use, potential for abuse, and safety or dependence liability. Schedule I drugs have a high potential for abuse and the potential to create severe psychological and\/or physical dependence, whereas Schedule V drugs represent the least potential for abuse. Sample medications for each schedule are summarized in Table 2.3.<sup><a class=\"footnote\" title=\"U.S. Department of Justice - Drug Enforcement Administration. (n.d.). Drug scheduling. https:\/\/www.dea.gov\/drug-scheduling\" id=\"return-footnote-69-6\" href=\"#footnote-69-6\" aria-label=\"Footnote 6\"><sup class=\"footnote\">[6]<\/sup><\/a><\/sup><\/p>\n<p>Table 2.3 Definitions and Sample Medications for Each Type of Scheduled Medication<\/p>\n<table class=\"grid\">\n<tbody>\n<tr>\n<th class=\"shaded\" scope=\"col\">\n<h5><strong>Schedule<\/strong><\/h5>\n<\/th>\n<th class=\"shaded\" scope=\"col\">\n<h5><strong>Definition<\/strong><\/h5>\n<\/th>\n<th class=\"shaded\" scope=\"col\">\n<h5><strong>Examples<\/strong><\/h5>\n<\/th>\n<\/tr>\n<tr>\n<th scope=\"row\">Schedule\u00a0I<\/th>\n<td>No currently accepted medical use and a high potential for abuse.<\/td>\n<td>Heroin, LSD, and marijuana<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Schedule\u00a0II<\/th>\n<td>High potential for abuse, with use potentially leading to severe psychological or physical dependence. These drugs are also considered dangerous.<\/td>\n<td>Vicodin, cocaine, methamphetamine, methadone, hydromorphone (Dilaudid), meperidine (Demerol), oxycodone (OxyContin), fentanyl, Dexedrine, Adderall, and Ritalin<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Schedule\u00a0III<\/th>\n<td>Moderate to low potential for physical and psychological dependence. Abuse potential is less than Schedule I and Schedule II drugs but more than Schedule IV.<\/td>\n<td>Tylenol with codeine, ketamine, anabolic steroids, and testosterone<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Schedule\u00a0IV<\/th>\n<td>Low potential for abuse and low risk of dependence.<\/td>\n<td>Xanax, Soma, Valium, Ativan, Talwin, Ambien, and Tramadol<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Schedule\u00a0V<\/th>\n<td>Lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics. Generally used for antidiarrheal, antitussive, and analgesic purposes.<\/td>\n<td>Robitussin AC with codeine, Lomotil, and Lyrica<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div class=\"textbox\">\n<p class=\"arrow\">Read more information about <a href=\"https:\/\/www.dea.gov\/drug-scheduling\" target=\"_blank\" rel=\"noopener\">Drug Scheduling<\/a> on the DEA website and view an alphabetic listing of drugs and their schedule.<sup><a class=\"footnote\" title=\"U.S. Department of Justice - Drug Enforcement Administration. (n.d.). Drug scheduling. https:\/\/www.dea.gov\/drug-scheduling\" id=\"return-footnote-69-7\" href=\"#footnote-69-7\" aria-label=\"Footnote 7\"><sup class=\"footnote\">[7]<\/sup><\/a>,<a class=\"footnote\" title=\"U.S. Department of Justice - Drug Enforcement Administration. (2023). Controlled substances. https:\/\/www.deadiversion.usdoj.gov\/schedules\/orangebook\/c_cs_alpha.pdf\" id=\"return-footnote-69-8\" href=\"#footnote-69-8\" aria-label=\"Footnote 8\"><sup class=\"footnote\">[8]<\/sup><\/a><\/sup><\/p>\n<\/div>\n<p>Drug overdose continues to be a public health crisis in the United States. The misuse of prescription opioids contributes to a large percentage of overdose deaths. Many problems associated with substance use are the result of legitimately made controlled substances being diverted from their lawful purpose into illicit drug traffic. The mission of DEA&#8217;s Diversion Control Division is to prevent, detect, and investigate the diversion of controlled medications from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs. The DEA provides education regarding related topics that apply to nurses such as drug diversion, state prescription drug monitoring systems, current drug trends, and proper drug disposal.<sup><a class=\"footnote\" title=\"U.S. Department of Justice - Drug Enforcement Administration. (2023). Controlled substances. https:\/\/www.deadiversion.usdoj.gov\/schedules\/orangebook\/c_cs_alpha.pdf\" id=\"return-footnote-69-9\" href=\"#footnote-69-9\" aria-label=\"Footnote 9\"><sup class=\"footnote\">[9]<\/sup><\/a><\/sup><\/p>\n<h4><a id=\"_uofazniim8wd\" href=\"\"><\/a>Drug Diversion<\/h4>\n<p>Drug diversion involves the transfer of any legally prescribed controlled substance from the individual for whom it was prescribed to another person for any illicit use. The most commonly diverted substances in health care facilities are opioids. Diversion of controlled substances can result in substantial risk, not only to the individual who is diverting the drugs, but also to clients, coworkers, and employers. Impaired health professionals can harm clients by providing substandard care or exposing clients to tainted substances.<\/p>\n<p>Tampering is the riskiest and most harmful type of diversion. Tampering occurs when the diverter removes medication from a syringe, vial, or other container and injects themselves with the medication. The diverter then replaces the stolen medication with saline, sterile water, or another clear liquid. The replaced liquid is then unknowingly administered to the client by an unaware nurse.<sup><a class=\"footnote\" title=\"New, K. (2014, June 3). Drug diversion defined: A patient safety threat. Centers for Disease Control and Prevention. https:\/\/web.archive.org\/web\/20150716073835\/http:\/\/blogs.cdc.gov\/safehealthcare\/2014\/06\/03\/drug-diversion-defined-a-patient-safety-threat\/\" id=\"return-footnote-69-10\" href=\"#footnote-69-10\" aria-label=\"Footnote 10\"><sup class=\"footnote\">[10]<\/sup><\/a>,<a class=\"footnote\" title=\"Berge, K. H., Dillon, K. R., Sikkink, K. M., Taylor, T. K., &amp; Lanier, W. L. (2012). Diversion of drugs within health care facilities, a multiple-victim crime: Patterns of diversion, scope, consequences, detection, and prevention. Mayo Clinic Proceedings, 87(7), 674\u2013682. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22766087\" id=\"return-footnote-69-11\" href=\"#footnote-69-11\" aria-label=\"Footnote 11\"><sup class=\"footnote\">[11]<\/sup><\/a><\/sup><\/p>\n<p>The DEA provides an online reporting form for individuals to report suspected drug diversion anonymously.<sup> <a class=\"footnote\" title=\"U.S. Department of Justice - Drug Enforcement Administration. (n.d.). https:\/\/www.deadiversion.usdoj.gov\/prog_dscrpt\/index.html\" id=\"return-footnote-69-12\" href=\"#footnote-69-12\" aria-label=\"Footnote 12\"><sup class=\"footnote\">[12]<\/sup><\/a><\/sup><\/p>\n<div class=\"textbox\">\n<p class=\"arrow\">View the <a href=\"https:\/\/apps2.deadiversion.usdoj.gov\/rxaor\/spring\/main?execution=e2s1\" target=\"_blank\" rel=\"noopener\">RX Abuse Online Reporting form<\/a> to report drug diversion to the DEA.<sup><a class=\"footnote\" title=\"U.S. Department of Justice - Drug Enforcement Administration. (n.d.). RX abuse online reporting: Report incident. https:\/\/apps2.deadiversion.usdoj.gov\/rxaor\/spring\/main?execution=e1s1\" id=\"return-footnote-69-13\" href=\"#footnote-69-13\" aria-label=\"Footnote 13\"><sup class=\"footnote\">[13]<\/sup><\/a><\/sup><\/p>\n<\/div>\n<h5>Substance Use Disorder in Health Professionals<\/h5>\n<p>Substance use disorder (SUD) is an illness caused by repeated misuse of substances such as cannabis, opioids, sedatives, and stimulants. Substances taken in excess have a common effect of directly activating the brain reward system and producing such an intense activation of the reward system that normal life activities may be neglected.<sup><a class=\"footnote\" title=\"American Psychiatric Association. (2013). Desk reference to the diagnostic criteria from DSM-5.\" id=\"return-footnote-69-14\" href=\"#footnote-69-14\" aria-label=\"Footnote 14\"><sup class=\"footnote\">[14]<\/sup><\/a><\/sup><\/p>\n<p>Health care professionals are not immune to developing SUD. It is important for nurses to be aware of the warning signs of SUD and to understand that SUD is a disease that can affect anyone regardless of age, occupation, economic circumstances, ethnic background, or gender. In most states, a nurse with SUD may voluntarily enter a professional assistance program for evaluation and treatment.<sup><a class=\"footnote\" title=\"National Council of State Boards of Nursing (NCSBN). (2018). A nurse's guide to substance use disorder in nursing. https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf\" id=\"return-footnote-69-15\" href=\"#footnote-69-15\" aria-label=\"Footnote 15\"><sup class=\"footnote\">[15]<\/sup><\/a><\/sup> Read more about professional assistance programs under the &#8220;State Law, State Nurse Practice Acts, and State Boards of Nursing&#8221; subsection below.<\/p>\n<p>The National Council of State Boards of Nursing (NCSBN) created <em>A Nurse&#8217;s Guide to Substance Use Disorder in Nursing<\/em> brochure that states many nurses with substance use disorder (SUD) are unidentified, unreported, untreated, and may continue to practice where their impairment may endanger the lives of their clients or themselves. It can be hard to differentiate between the subtle signs of impairment and stress-related behaviors, but three areas to watch for suspected SUD are behavior changes, physical signs, and drug diversion. Behavioral changes can include changes or shifts in job performance, absences from the unit for extended periods, frequent trips to the bathroom, arriving late or leaving early, and making an excessive number of mistakes, including medication errors. Physical signs include subtle changes in appearance that may escalate over time, increasing isolation from colleagues, inappropriate verbal or emotional responses, and diminished alertness, confusion, or memory lapses. When nurses with SUD commit drug diversion, there are often discrepancies that colleagues notice, such as incorrect opioid counts, a pattern of large amounts of opioid wastage, numerous corrections of medication records, frequent reports of ineffective pain relief from clients assigned to that nurse, increased agitation\/combativeness of assigned clients with dementia, and patterns of increased administration of opioids to clients when that nurse is scheduled to work.<sup><a class=\"footnote\" title=\"National Council of State Boards of Nursing (NCSBN). (2018). A nurse's guide to substance use disorder in nursing. https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf\" id=\"return-footnote-69-16\" href=\"#footnote-69-16\" aria-label=\"Footnote 16\"><sup class=\"footnote\">[16]<\/sup><\/a><\/sup><\/p>\n<p>As a student nurse and nurse, you have a professional and ethical responsibility to report a colleague&#8217;s suspected SUD to your supervisor and, in some states or jurisdictions, to the State Board of Nursing. The earlier that SUD is identified in a nurse and treatment is started, the sooner clients are protected, and the better the chances for the nurse with SUD to recover and safely return to work.<sup><a class=\"footnote\" title=\"National Council of State Boards of Nursing (NCSBN). (2018). A nurse's guide to substance use disorder in nursing. https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf\" id=\"return-footnote-69-17\" href=\"#footnote-69-17\" aria-label=\"Footnote 17\"><sup class=\"footnote\">[17]<\/sup><\/a><\/sup><\/p>\n<div class=\"textbox\">\n<p class=\"arrow\">Visit the NCSBN&#8217;s website to read <a href=\"https:\/\/www.ncsbn.org\/nursing-regulation\/practice\/substance-use-disorder\/sud-educational-materials.page\" target=\"_blank\" rel=\"noopener\">&#8220;A Nurse&#8217;s Guide to Substance Use Disorder in Nursing&#8221;<\/a> brochure.<\/p>\n<\/div>\n<h3><a id=\"_lgp5f0df7kyk\" href=\"\"><\/a>Drug Disposal Act<\/h3>\n<p>The Secure and Responsible Drug Disposal Act of 2010 allows users to dispose of controlled substances in a safe and effective manner. A Johns Hopkins study on sharing of medication found that 60% of people had leftover opioids they saved for future use; 20% shared their medications; 8% would likely share with a friend; 14% would likely share with a relative; and only 10% securely locked their medication.<sup><a class=\"footnote\" title=\"U.S. Department of Justice - Drug Enforcement Administration. (2017, December 13). Federal regulations and the disposal of controlled substances. https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal\" id=\"return-footnote-69-18\" href=\"#footnote-69-18\" aria-label=\"Footnote 18\"><sup class=\"footnote\">[18]<\/sup><\/a><\/sup> This act has resulted in \u201cNational Take Back Days\u201d in all 50 states, as well as new collection receptacles.<sup><a class=\"footnote\" title=\"U.S. Department of Justice - Drug Enforcement Administration. (2017, December 13). Federal regulations and the disposal of controlled substances. https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal\" id=\"return-footnote-69-19\" href=\"#footnote-69-19\" aria-label=\"Footnote 19\"><sup class=\"footnote\">[19]<\/sup><\/a><\/sup><\/p>\n<p>To prevent risk of drug diversion, nurses should teach clients who are prescribed controlled substances how to dispose of them properly so that they don&#8217;t end up being misused or overdosed by another person. Figure 2.2<sup><a class=\"footnote\" title=\"\u201cMedRx box.JPG\u201d by York Police is licensed under CC0\" id=\"return-footnote-69-20\" href=\"#footnote-69-20\" aria-label=\"Footnote 20\"><sup class=\"footnote\">[20]<\/sup><\/a><\/sup> shows an example of a controlled substances collection receptacle.<sup><a class=\"footnote\" title=\"U.S. Department of Justice - Drug Enforcement Administration. (2017, December 13). Federal regulations and the disposal of controlled substances. https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal\" id=\"return-footnote-69-21\" href=\"#footnote-69-21\" aria-label=\"Footnote 21\"><sup class=\"footnote\">[21]<\/sup><\/a><\/sup><\/p>\n<figure style=\"width: 296px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" title=\"&quot;MedRx box.JPG&quot; by York Police is licensed under CC0\" src=\"https:\/\/pressbooks.ccconline.org\/accdigitalmarketing\/wp-content\/uploads\/sites\/219\/2025\/01\/image9-2.png\" alt=\"Photograph of a controlled substances collection receptacle\" width=\"296\" height=\"403\" \/><figcaption class=\"wp-caption-text\">Figure 2.2 Controlled Substances Collection Receptacle<\/figcaption><\/figure>\n<div class=\"textbox textbox--examples\">\n<header class=\"textbox__header\">\n<h2>Critical Thinking Activity 2.3b<img loading=\"lazy\" decoding=\"async\" class=\"alignright size-thumbnail wp-image-67\" src=\"https:\/\/pressbooks.ccconline.org\/accdigitalmarketing\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-150x150.png\" alt=\"Image of a circle containing a speech bubble with a question mark in it.\" width=\"150\" height=\"150\" srcset=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-150x150.png 150w, https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-65x65.png 65w, https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-225x225.png 225w, https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1.png 300w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/h2>\n<\/header>\n<div class=\"textbox__content\" style=\"text-align: left\">\n<ol>\n<li>A nurse is providing discharge education to a client who recently had surgery and has been prescribed hydrocodone\/acetaminophen tablets to take every four hours as needed at home. The nurse explains that when the medication is no longer needed when the post-op pain subsides, it should be dropped off at a local pharmacy for disposal in a collection receptacle. The client states, \u201cI don&#8217;t like to throw anything away. I usually keep unused medication in case another family member needs it.\u201d<br \/>\nWhat is the nurse&#8217;s best response?<\/li>\n<li>A nurse begins a new job on a medical-surgical unit. One of the charge nurses on this unit is highly regarded by her colleagues and appears to provide excellent care to her clients. The new nurse cares for a client whom the charge nurse cared for on the previous shift. The new nurse asks the client about the effectiveness of the pain medication documented as provided by the charge nurse during the previous shift. The client states, \u201cI didn&#8217;t receive any pain medication during the last shift.\u201d The nurse mentions this incident to a preceptor who states, \u201cI have noticed that the same types of incidents have occurred with previous clients but didn&#8217;t want to say anything.\u201d<br \/>\nWhat is the new nurse&#8217;s best response?<\/li>\n<\/ol>\n<p>Note: Answers to the Critical Thinking activities can be found in the \u201c<a href=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/chapter-2\/\" target=\"_blank\" rel=\"noopener\">Answer Key<\/a>\u201d section at the end of the book.<\/p>\n<\/div>\n<\/div>\n<h3><a id=\"_w83njfnfsik1\" href=\"\"><\/a>The Joint Commission<\/h3>\n<p><strong><a class=\"glossary-term\" aria-haspopup=\"dialog\" aria-describedby=\"definition\" href=\"#term_69_723\">The Joint Commission<\/a>\u00a0<\/strong>is a national organization that accredits and certifies over 20,000 health care organizations in the United States. The mission of The Joint Commission is to continuously improve health care for the public by inspiring health care organizations to excel in providing safe and effective care of the highest quality and value.<sup><a class=\"footnote\" title=\"The Joint Commission. (n.d.). https:\/\/www.jointcommission.org\/\" id=\"return-footnote-69-22\" href=\"#footnote-69-22\" aria-label=\"Footnote 22\"><sup class=\"footnote\">[22]<\/sup><\/a><\/sup> Some of The Joint Commission&#8217;s national initiatives regarding medication safety include creating a &#8220;Safety Culture&#8221; in health care organizations with associated root cause analysis, the Speak Up Campaign, National Patient Safety Goals, and the Official Do not Use List. Each of these safety initiatives is further discussed in the following subsections.<\/p>\n<h4><a id=\"_p2pv81uos5cy\" href=\"\"><\/a>Safety Culture<\/h4>\n<p>The Joint Commission Center for Transforming Healthcare develops effective solutions for health care&#8217;s most critical safety and quality problems with a goal to ultimately achieve zero harm to clients. Some of the projects the Center has developed include improved hand hygiene,<sup><a class=\"footnote\" title=\"Joint Commission Center for Transforming Healthcare. (2020). Hand hygiene. https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/hand-hygiene\" id=\"return-footnote-69-23\" href=\"#footnote-69-23\" aria-label=\"Footnote 23\"><sup class=\"footnote\">[23]<\/sup><\/a><\/sup> effective handoff communications,<sup><a class=\"footnote\" title=\"Joint Commission Center for Transforming Healthcare. (2020.) Effective hand-off communications. https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/hand-off-communications\" id=\"return-footnote-69-24\" href=\"#footnote-69-24\" aria-label=\"Footnote 24\"><sup class=\"footnote\">[24]<\/sup><\/a><\/sup> and safe and effective use of insulin.<sup><a class=\"footnote\" title=\"Joint Commission Center for Transforming Healthcare. (2020). Safe and effective use of insulin. https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/safe-and-effective-use-of-insulin\" id=\"return-footnote-69-25\" href=\"#footnote-69-25\" aria-label=\"Footnote 25\"><sup class=\"footnote\">[25]<\/sup><\/a> <\/sup><\/p>\n<p>The Center has also been instrumental in building a focus on creating a \u201cSafety Culture\u201d in health care organizations. A <strong><a class=\"glossary-term\" aria-haspopup=\"dialog\" aria-describedby=\"definition\" href=\"#term_69_625\">Safety Culture<\/a><\/strong> empowers staff to speak up about risks to clients and to report errors and near misses. These actions reduce the risk of client harm. According to the Institute of Medicine, \u201cThe biggest challenge to moving toward a safer health system is changing the culture from one of blaming individuals for errors to one in which errors are treated not as personal failures, but as opportunities to improve the system and prevent harm.\u201d<sup><a class=\"footnote\" title=\"The Joint Commission. (2014, November). Facts about the safety culture project. https:\/\/www.centerfortransforminghealthcare.org\/-\/media\/cth\/documents\/improvement-topics\/cth_sc_fact_sheet.pdf\" id=\"return-footnote-69-26\" href=\"#footnote-69-26\" aria-label=\"Footnote 26\"><sup class=\"footnote\">[26]<\/sup><\/a>\u00a0\u00a0<\/sup><\/p>\n<div class=\"textbox\">\n<p class=\"arrow\">Visit the <a href=\"https:\/\/www.jointcommission.org\/what-we-offer\/accreditation\/accredited\/accreditation-announcements-and-updates\/safety-culture-assessment-improving-the-survey-process\/\" target=\"_blank\" rel=\"noopener\">Joint Commission&#8217;s Safety Culture Assessment webpage<\/a> to learn more.<\/p>\n<\/div>\n<p>A component of Safety Culture is the submission of incident reports according to agency guidelines whenever a medication error or a \u201cnear miss\u201d occurs. A near miss is a narrowly avoided error. The incident report triggers a <strong><a class=\"glossary-term\" aria-haspopup=\"dialog\" aria-describedby=\"definition\" href=\"#term_69_548\">root cause analysis<\/a><\/strong> by the organization to identify not only what and how an event occurred, but also why it happened. When investigators determine why an error occurred, they can create workable corrective measures to prevent future errors from occurring.<sup><a class=\"footnote\" title=\"Patient Safety Network. (2019). Root cause analysis. https:\/\/psnet.ahrq.gov\/primer\/root-cause-analysis\" id=\"return-footnote-69-27\" href=\"#footnote-69-27\" aria-label=\"Footnote 27\"><sup class=\"footnote\">[27]<\/sup><\/a><\/sup><\/p>\n<p>An example of Safety Culture in action is a tragic event in 2006, when three infants died after incorrect heparin doses were used to flush their vascular access devices. A root cause analysis found that pharmacy technicians accidentally placed vials containing concentrated heparin (10,000 units\/mL) in medication storage locations that were designated for less concentrated heparin vials (10 units\/mL). Additionally, the heparin vials were similar in appearance, so the nurses did not notice the incorrect dosage until after it was administered. In response to a root cause analysis, the hospital no longer stores vials of heparin in pediatric units and uses saline to flush all peripheral lines. In the pharmacy, 10,000 units\/mL heparin vials were separated from vials containing other strengths. In this manner, corrective measures were implemented to prevent future tragedies from occurring as a result of incorrect doses of heparin.<sup><a class=\"footnote\" title=\"Institute for Safe Medication Practices. (2007, November 29). Another heparin error: Learning from mistakes so we don't repeat them. https:\/\/www.ismp.org\/resources\/another-heparin-error-learning-mistakes-so-we-dont-repeat-them\" id=\"return-footnote-69-28\" href=\"#footnote-69-28\" aria-label=\"Footnote 28\"><sup class=\"footnote\">[28]<\/sup><\/a><\/sup><\/p>\n<h4><a id=\"_d1kdgcsew13b\" href=\"\"><\/a>Speak Up Campaign<\/h4>\n<p>The goal of The Joint Commission&#8217;s Speak Up\u2122 campaign is to help clients become more informed and involved in their health care to prevent medication errors. Speak Up\u2122 materials are intended for the public and have been put into a simplified, easy-to-read format to reach a wider audience.<sup><a class=\"footnote\" title=\"The Joint Commission. (n.d.). Speak up campaigns. https:\/\/www.jointcommission.org\/resources\/for-consumers\/speak-up-campaigns\/#sort=%40z95xz95xcontentdate%20descending\" id=\"return-footnote-69-29\" href=\"#footnote-69-29\" aria-label=\"Footnote 29\"><sup class=\"footnote\">[29]<\/sup><\/a><\/sup><\/p>\n<div class=\"textbox\">\n<p class=\"arrow\">Request additional &#8220;SpeakUp&#8221; materials from <a href=\"https:\/\/www.jointcommission.org\/resources\/news-and-multimedia\/fact-sheets\/facts-about-speak-up\/\" target=\"_blank\" rel=\"noopener\">The Joint Commission Speak Up Fact Sheet webpage<\/a>.<\/p>\n<\/div>\n<h4><a id=\"_gdkgehf16byc\" href=\"\"><\/a>National Patient Safety Goals<\/h4>\n<p>The <strong><a class=\"glossary-term\" aria-haspopup=\"dialog\" aria-describedby=\"definition\" href=\"#term_69_549\">National Patient Safety Goals <\/a> (NPSG)<\/strong> are established by The Joint Commission to help accredited organizations address current areas of concern related to patient safety. Annually, The Joint Commission determines the current highest priority patient safety issues with input from practitioners, provider organizations, purchasers, consumer groups, and other stakeholders and develops National Patient Safety Goals.<\/p>\n<p>Two of the current National Patient Safety Goals relate specifically to medication administration: &#8220;Identify Patients Correctly&#8221; and &#8220;Use Medicines Safely.&#8221;<\/p>\n<div class=\"textbox\">\n<p class=\"arrow\">Review The Joint Commission&#8217;s <a href=\"https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" target=\"_blank\" rel=\"noopener\">National Patient Safety Goals for Hospitals PDF<\/a><sup><a class=\"footnote\" title=\"The Joint Commission. (2023). 2023 hospital national patient safety goals. https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" id=\"return-footnote-69-30\" href=\"#footnote-69-30\" aria-label=\"Footnote 30\"><sup class=\"footnote\">[30]<\/sup><\/a><\/sup><\/p>\n<\/div>\n<h5>Identify Patients Correctly<\/h5>\n<p>Nurses and health care professionals must use at least two ways to identify clients. For example, use the client&#8217;s name and date of birth. This is done to make sure that each client gets the correct medicine and treatment.<sup><a class=\"footnote\" title=\"The Joint Commission. (2023). 2023 hospital national patient safety goals. https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" id=\"return-footnote-69-31\" href=\"#footnote-69-31\" aria-label=\"Footnote 31\"><sup class=\"footnote\">[31]<\/sup><\/a><\/sup><\/p>\n<h5>Use Medicines Safely<\/h5>\n<p>Before a procedure, label medications that are not labeled. For example, medications in syringes, cups, and basins should be labelled in the area where medications and supplies are set up. Labels should include medication name, dose, date drawn up, and initials of the person who prepared the medication.<sup><a class=\"footnote\" title=\"The Joint Commission. (2023). 2023 hospital national patient safety goals. https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" id=\"return-footnote-69-32\" href=\"#footnote-69-32\" aria-label=\"Footnote 32\"><sup class=\"footnote\">[32]<\/sup><\/a><\/sup> Additionally, do not leave medications unattended.<\/p>\n<p>Record and pass along correct information about a client&#8217;s medications. Find out what medications the client is taking. Compare those medications to new medications given to the client. Make sure the client knows which medications to take when they are at home. Tell the client it is important to bring their up-to-date list of medications every time they visit a doctor. Extra care must be taken with clients who take medications to thin their blood (anticoagulants).<sup><a class=\"footnote\" title=\"The Joint Commission. (2023). 2023 hospital national patient safety goals. https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" id=\"return-footnote-69-33\" href=\"#footnote-69-33\" aria-label=\"Footnote 33\"><sup class=\"footnote\">[33]<\/sup><\/a><\/sup><\/p>\n<h4><a id=\"_xgxlubfdu0h2\" href=\"\"><\/a>The Joint Commission&#8217;s Official Do Not Use List<\/h4>\n<p>The Joint Commission maintains an Official Do Not Use List of abbreviations. These abbreviations have been found to commonly cause errors in client care. Accredited agencies are expected to not use these abbreviations on any written or preprinted materials.<sup><a class=\"footnote\" title=\"The Joint Commission. (2023). Do not use list fact sheet. https:\/\/www.jointcommission.org\/facts_about_do_not_use_list\/\" id=\"return-footnote-69-34\" href=\"#footnote-69-34\" aria-label=\"Footnote 34\"><sup class=\"footnote\">[34]<\/sup><\/a><\/sup><\/p>\n<div class=\"textbox\">\n<p class=\"arrow\">Read The Joint Commission&#8217;s\u00a0 <a href=\"https:\/\/www.jointcommission.org\/resources\/news-and-multimedia\/fact-sheets\/facts-about-do-not-use-list\/\" target=\"_blank\" rel=\"noopener\">Official Do Not Use List Fact Sheet<\/a><\/p>\n<\/div>\n<h3>CMS: Centers for Medicare and Medicaid Services<\/h3>\n<p>The Centers for Medicare &amp; Medicaid Services (CMS) is a federal agency within the United States Department of Health and Human Services (HHS). The CMS administers the Medicare program and works in partnership with state governments to administer Medicaid and establishes and enforces regulations to protect client safety in hospitals that receive Medicare and Medicaid funding.<sup><a class=\"footnote\" title=\"U.S. Department of Health &amp; Human Services, Centers for Medicare &amp; Medicaid Services. (2014). Memo: Requirements for hospital medication administration, particularly intravenous (IV) medications and post-operative care of patients receiving IV opioids. https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf\" id=\"return-footnote-69-35\" href=\"#footnote-69-35\" aria-label=\"Footnote 35\"><sup class=\"footnote\">[35]<\/sup><\/a><\/sup><\/p>\n<p>CMS regulations related to the administration of medication by nurses include verifying information included in the prescription for a medication, checking the rights of medication administration, reporting concerns about a medication prescription, assessing and monitoring clients receiving medications, and documenting medication administration. Each of these regulations is further discussed below.<\/p>\n<h4><a id=\"_d8fnzu4041iw\" href=\"\"><\/a>Verifying Prescriptions<\/h4>\n<p>Medications and biologicals are administered in response to a prescription from a health care provider or on the basis of a standing order that is subsequently authenticated by a provider. Biologicals are a diverse group of medications that include vaccines, growth factors, immune modulators, monoclonal antibodies, and products derived from blood and plasma. All provider orders for the administration of drugs and biologicals must include the following:<\/p>\n<ul>\n<li>Name of the client<\/li>\n<li>Age and weight of the client to facilitate dose calculation when applicable. Agency policies and procedures must address weight-based dosing for pediatric client. Dose calculations for newborns are typically based on the metric weight in grams.<\/li>\n<li>Date and time of the order<\/li>\n<li>Drug name<\/li>\n<li>Dose, frequency, and route<\/li>\n<li>Dose calculation requirements, when applicable<\/li>\n<li>Exact strength or concentration, when applicable<\/li>\n<li>Quantity and\/or duration, when applicable<\/li>\n<li>Specific instructions for use, when applicable<\/li>\n<li>Name of the provider<\/li>\n<\/ul>\n<h4><a id=\"_bbpddzg21jjr\" href=\"\"><\/a>Checking The Rights of Medication Administration<\/h4>\n<p>The CMS states that agency policies and procedures must reflect accepted standards of practice that require specific information is confirmed prior to administration of medication. This is commonly referred to as &#8220;checking the rights of medication administration.&#8221;<\/p>\n<p>When administering medications, it is essential for nurses to vigilantly check the rights of medication administration at least three times to prevent medication errors. What historically began as checking five rights of mediation administration has been extended to eight rights according to the American Nurses Association. These eight rights include the following<sup><a class=\"footnote\" title=\"American Nurses Association. (2021). ANA issue brief: Use of medication assistants\/aides\/technicians. https:\/\/www.nursingworld.org\/~498e32\/contentassets\/a2ff1bd2d5ca467699c3bc764f7d9198\/issue-brief-medication-aides-4-2021.docx\" id=\"return-footnote-69-36\" href=\"#footnote-69-36\" aria-label=\"Footnote 36\"><sup class=\"footnote\">[36]<\/sup><\/a><\/sup>:<\/p>\n<ul>\n<li><strong>Right patient:<\/strong> Check that you have the correct client using two patient identifiers according to agency policy (e.g., name and date of birth).<\/li>\n<li style=\"font-weight: 400\"><strong>Right medication:<\/strong> Check that you have the correct medication and that it is appropriate for the patent in the current context. Understand the purpose of the medication and why the client is receiving it.<\/li>\n<li style=\"font-weight: 400\"><strong>Right dose:<\/strong> Check that the dose is safe for the age, size, and condition of the client. Different dosages may be indicated for different conditions, and pediatric dosages are typically much lower than adult dosages.<\/li>\n<li style=\"font-weight: 400\"><strong>Right route:<\/strong> Check that the route is appropriate for the client\u2019s current condition.<\/li>\n<li style=\"font-weight: 400\"><strong>Right time:<\/strong> Adhere to the prescribed scheduling of the medication.<\/li>\n<li style=\"font-weight: 400\"><strong>Right documentation:<\/strong> Always verify any unclear or inaccurate documentation prior to administering medications.<\/li>\n<li><strong>Right reason:<\/strong> Verify this medication is being administered to this client at this time for the right reason. If signs and symptoms no longer warrant administration of the prescribed medication, notify the prescribing provider.<\/li>\n<li><strong>Right response: <\/strong>After administering medication, the nurse must evaluate for expected outcomes with the time frame of expected onset and peak. The onset of medication administration occurs when the action of the medication begins to take effect. The peak of the medication administration occurs when the medication is at the highest level in the client\u2019s bloodstream. It is important for nurses to be aware of both the peak and onset of medications to know when the client&#8217;s response to medication may start to be observed. The nurse must also be aware of potential side effects and adverse effects and evaluate for these unexpected outcomes. The prescribing provider should be notified if expected outcomes are not achieved or if adverse effects occur.<\/li>\n<\/ul>\n<p>Many agencies have implemented barcode medication scanning to improve safety during medication administration. Barcode scanning systems reduce medication errors by electronically verifying the \u201crights\u201d of medication administration. For example, when a nurse scans a barcode on the client&#8217;s wristband and on the medication to be administered, the data is delivered to a computer software system where algorithms check databases and generate real-time warnings or approvals. Barcode scanning reduces errors resulting from administration of a wrong medication, incorrect dose, or wrong route. However, it is important for nurses to remember that barcode scanning should be used in addition to checking the rights of medication administration, not in place of this important safety process. Additionally, nurses should carefully consider their actions when errors occur during the barcode scanning process. Although it may be tempting to quickly dismiss the error and attribute it to a technology glitch, the error may have been triggered due to a patient safety concern that requires further follow-up before the medication is administered. Nurses must investigate errors that occur during the barcode scanning process just as they would do if an error were discovered while checking the rights of medication administration.<\/p>\n<div class=\"textbox\">\n<p class=\"video\">View a supplementary YouTube video<sup><a class=\"footnote\" title=\"Kimberly Dunker. (2020, April 6). Mediation Administration. [Video]. YouTube. All rights reserved. https:\/\/youtu.be\/MUn4Ec2X93g\" id=\"return-footnote-69-37\" href=\"#footnote-69-37\" aria-label=\"Footnote 37\"><sup class=\"footnote\">[37]<\/sup><\/a><\/sup> example of a student preparing to administer medication and checking the rights of medication administration: <a href=\"https:\/\/youtu.be\/MUn4Ec2X93g\" target=\"_blank\" rel=\"noopener\">Medication Administration.<\/a><\/p>\n<\/div>\n<h4><a id=\"_4sfkusc12i7o\" href=\"\"><\/a>Communicating Concerns About Medication Orders<\/h4>\n<p>The CMS encourages hospitals to promote a culture in which it is not only acceptable, but also strongly encouraged, for staff to notify prescribing providers regarding concerns they have regarding medication orders.<sup><a class=\"footnote\" title=\"U.S. Department of Health &amp; Human Services, Centers for Medicare &amp; Medicaid Services. (2014). Memo: Requirements for hospital medication administration, particularly intravenous (IV) medications and post-operative care of patients receiving IV opioids. https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf\" id=\"return-footnote-69-38\" href=\"#footnote-69-38\" aria-label=\"Footnote 38\"><sup class=\"footnote\">[38]<\/sup><\/a><\/sup> It is essential for nurses to contact the prescribing provider if they have any concerns when checking the rights of medication administration before administering the medication to the client. Furthermore, nurses can be held liable in a court of law if they administer medication that results in client harm if a &#8220;prudent nurse&#8221; would have had concerns about the order and questioned it.<\/p>\n<h4><a id=\"_gdcisn9j8vzp\" href=\"\"><\/a>Monitoring Clients Receiving Medications<\/h4>\n<p>The CMS states that observing the effects medications have on the client is part of the multifaceted medication administration process. Clients must be carefully monitored to determine whether the medication results in the therapeutically intended benefit and to allow for early identification of adverse effects and timely initiation of appropriate corrective action. Depending on the medication and route\/delivery mode, monitoring may include assessment of the following:<\/p>\n<ul>\n<li>Clinical and laboratory data to evaluate the efficacy of medication therapy, potential toxicity, and adverse effects. For some medications, such as opioids, this monitoring may include clinical data such as respiratory status, blood pressure, and oxygenation and carbon dioxide levels.<\/li>\n<li>Physical signs and clinical symptoms relevant to the client&#8217;s medication therapy, such as confusion, agitation, unsteady gait, pruritus, etc.<\/li>\n<li>Factors contributing to high risk for adverse drug events. The consequences of errors can be harmful and sometimes fatal to clients. In addition, certain factors place some clients at greater risk for adverse effects of medication. These factors include, but are not limited to, age, altered liver and kidney function, drug-to-drug interactions, and first-time medication use.<\/li>\n<\/ul>\n<p>The nurse should consider client risk factors, as well as the risks inherent in a medication, when determining the type and frequency of monitoring. It is also essential to communicate information regarding client medication risk factors and monitoring requirements during hand-off reports to other staff.<\/p>\n<p>Adverse client reactions, such as anaphylaxis or opioid-induced sedation and respiratory depression, require timely and appropriate intervention per agency protocols and should also be immediately reported to the prescribing provider. An example of vigilant post-medication administration monitoring is when a nurse closely monitors a post-surgical client who is receiving opioid pain medication via a patient-controlled analgesia (PCA) pump. Opioid medications are used to control pain but also have a sedating effect. Clients can become overly sedated and suffer respiratory depression or arrest, which can be fatal. The nurse should closely monitor the client&#8217;s respiratory rate, oxygen saturation, carbon dioxide levels, level of sedation, blood pressure, and pulse to quickly observe and intervene in the event of an adverse event. In addition, the client and\/or family members are educated to notify nursing staff promptly when there is difficulty breathing or other changes that might be a reaction to medication.<sup><a class=\"footnote\" title=\"U.S. Department of Health &amp; Human Services, Centers for Medicare &amp; Medicaid Services. (2014). Memo: Requirements for hospital medication administration, particularly intravenous (IV) medications and post-operative care of patients receiving IV opioids. https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf\" id=\"return-footnote-69-39\" href=\"#footnote-69-39\" aria-label=\"Footnote 39\"><sup class=\"footnote\">[39]<\/sup><\/a><\/sup><\/p>\n<h4><a id=\"_lq4z5pjwif5d\" href=\"\"><\/a>Documenting<\/h4>\n<p>CMS regulations require the agency&#8217;s documentation regarding medication administration contains providers&#8217; orders, nursing notes, reports of treatment, medication administration records, radiology and laboratory reports, vital signs, and other information necessary to monitor the client&#8217;s condition. Documentation of medication administration is expected to occur immediately after the medication is administered to the client; documenting prior to the administration of the medication is inappropriate and can result in medication errors. Proper documentation of medication administration and client outcomes is essential for planning and delivering future care of the client.<sup><a class=\"footnote\" title=\"U.S. Department of Health &amp; Human Services, Centers for Medicare &amp; Medicaid Services. (2014). Memo: Requirements for hospital medication administration, particularly intravenous (IV) medications and post-operative care of patients receiving IV opioids. https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf\" id=\"return-footnote-69-40\" href=\"#footnote-69-40\" aria-label=\"Footnote 40\"><sup class=\"footnote\">[40]<\/sup><\/a>,<a class=\"footnote\" title=\"American Society of Health-System Pharmacists (Ed.). (2018). ASHP guidelines on preventing medication errors in hospitals. American Journal of Health-System Pharmacy, 75, 1493\u20131517. https:\/\/www.ashp.org\/-\/media\/assets\/policy-guidelines\/docs\/guidelines\/preventing-medication-errors-hospitals.ashx\" id=\"return-footnote-69-41\" href=\"#footnote-69-41\" aria-label=\"Footnote 41\"><sup class=\"footnote\">[41]<\/sup><\/a><\/sup><\/p>\n<div class=\"__UNKNOWN__\">\n<div class=\"textbox textbox--examples\">\n<header class=\"textbox__header\">\n<h2>Critical Thinking Activity 2.3c<img loading=\"lazy\" decoding=\"async\" class=\"alignright size-thumbnail wp-image-67\" src=\"https:\/\/pressbooks.ccconline.org\/accdigitalmarketing\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-150x150.png\" alt=\"Image of a circle containing a speech bubble with a question mark in it.\" width=\"150\" height=\"150\" srcset=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-150x150.png 150w, https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-65x65.png 65w, https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-225x225.png 225w, https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1.png 300w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/h2>\n<\/header>\n<div class=\"textbox__content\" style=\"text-align: left\">\n<p>A nurse is preparing to administer morphine, an opioid, to a client who recently had surgery.<\/p>\n<ol>\n<li>Explain the rights of medication administration the nurse must check prior to administering this medication to the client.<\/li>\n<li>Outline three methods the nurse can use to confirm patient identification.<\/li>\n<li>What should the nurse assess prior to administering this medication to the client?<\/li>\n<li>What should be monitored after administering this medication?<\/li>\n<li>What should the nurse teach the client (and\/or family member) about this medication?<\/li>\n<li>What information should be included in the shift handoff report about this medication?<\/li>\n<\/ol>\n<p>Note: Answers to the Critical Thinking activities can be found in the \u201c<a href=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/chapter-2\/\" target=\"_blank\" rel=\"noopener\">Answer Key<\/a>\u201d section at the end of the book.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<h2><a id=\"_i8t0mz3k0qmj\" href=\"\"><\/a>State Law, State Nurse Practice Acts, and State Boards of Nursing<\/h2>\n<p>In additional to federal laws, regulations, national guidelines, and safety initiatives, state law also protects public health and safety. Each state has a Nurse Practice Act (NPA) that is enacted by the state legislature. The State Board of Nursing (SBON) enforces the NPA.<sup><a class=\"footnote\" title=\"Wisconsin Department of Safety and Professional Services. (n.d.). Wisconsin nurse practice act (NPA) course. https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" id=\"return-footnote-69-42\" href=\"#footnote-69-42\" aria-label=\"Footnote 42\"><sup class=\"footnote\">[42]<\/sup><\/a><\/sup> The purpose of the SBON is to protect the public through licensure, education, legislation, and discipline regarding rules of conduct. The SBON regulates the licensure and practice of registered nurses (RNs), licensed practical\/vocational nurses (LPNs\/VNs), and advanced practice nurse prescribers (APNPs).<sup><a class=\"footnote\" title=\"Wisconsin Department of Safety and Professional Services. (n.d.). Wisconsin nurse practice act (NPA) course. https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" id=\"return-footnote-69-43\" href=\"#footnote-69-43\" aria-label=\"Footnote 43\"><sup class=\"footnote\">[43]<\/sup><\/a><\/sup><\/p>\n<p>Nurses are responsible for knowing the state laws that relate to nursing care in the state in which they work. Furthermore, nurses must follow the scope of practice outlined in the NPA in the state in which they are employed. Nurses are accountable for the quality of care they provide and are expected to practice at the level of education, knowledge, and skill of someone who has completed an approved nursing program. All nurses are expected to recognize the limits of their knowledge and experience and to appropriately address situations that are beyond their competency.<sup><a class=\"footnote\" title=\"Wisconsin Department of Safety and Professional Services. (n.d.). Wisconsin nurse practice act (NPA) course. https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" id=\"return-footnote-69-44\" href=\"#footnote-69-44\" aria-label=\"Footnote 44\"><sup class=\"footnote\">[44]<\/sup><\/a><\/sup><\/p>\n<div class=\"textbox\">\n<p class=\"arrow\">See an <a href=\"https:\/\/dsps.wi.gov\/Pages\/RulesStatutes\/Nursing.aspx\" target=\"_blank\" rel=\"noopener\">example of a Nurse Practice Act<\/a> established by the Wisconsin Board of Nursing.<sup><a class=\"rId37\" href=\"https:\/\/dsps.wi.gov\/Pages\/RulesStatutes\/Nursing.aspx\"><a class=\"footnote\" title=\"Wisconsin Department of Safety and Professional Services. (n.d.). Board of nursing Wisconsin Administrative Code.\u00a0https:\/\/dsps.wi.gov\/Pages\/RulesStatutes\/Nursing.aspx\" id=\"return-footnote-69-45\" href=\"#footnote-69-45\" aria-label=\"Footnote 45\"><sup class=\"footnote\">[45]<\/sup><\/a><\/a><\/sup><\/p>\n<\/div>\n<h3>Nurse<a id=\"_3apvx8llmlxh\" href=\"\"><\/a>\u00a0Practice Act: Standards of Practice<\/h3>\n<p>The NPA outlines the standards of care provided by a registered nurse (RN), also known as the <strong><a class=\"glossary-term\" aria-haspopup=\"dialog\" aria-describedby=\"definition\" href=\"#term_69_626\">nursing process<\/a><\/strong>. As previously discussed in this chapter, the steps of the nursing process are also considered a standard of care by the ANA. A nurse utilizes the nursing process when executing nursing care and procedures in the maintenance of clients&#8217; health, prevention of illness, or care of the ill. Review the steps of the nursing process in the &#8220;<a href=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/2-2-ethical-and-professional-foundations-of-safe-medication-administration-by-nurses\/\" target=\"_blank\" rel=\"noopener\">Ethical and Professional Foundations of Safe Medication Administration by Nurses<\/a>&#8221; section of this chapter.<\/p>\n<h3><a id=\"_cmg8l16gvfj9\" href=\"\"><\/a>Nurse Practice Act: Rules of Conduct<\/h3>\n<p>The NPA also outlines rules of conduct expected of nurses. Nurses can receive disciplinary action from the SBON, ranging from a reprimand to revocation of their license, if they do not follow the enacted rules of conduct. A nurse must maintain current knowledge about expected rules of conduct in each state where they practice nursing to protect their nursing license.<\/p>\n<div class=\"textbox\">\n<p class=\"arrow\">View an example of Rules of Conduct established in Chapter N7, <a href=\"https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/n\/7.pdf\" target=\"_blank\" rel=\"noopener\">&#8220;Rules of Conduct,&#8221; of the Wisconsin Nurse Practice Act PDF<\/a>.<sup><a class=\"footnote\" title=\"Wisconsin Department of Safety and Professional Services. (n.d.). Wisconsin nurse practice act (NPA) course. https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" id=\"return-footnote-69-46\" href=\"#footnote-69-46\" aria-label=\"Footnote 46\"><sup class=\"footnote\">[46]<\/sup><\/a>,<a class=\"footnote\" title=\"Wisconsin State Legislature. (2016, August). Chapter N7 rules of conduct. https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/n\/7.pdf\" id=\"return-footnote-69-47\" href=\"#footnote-69-47\" aria-label=\"Footnote 47\"><sup class=\"footnote\">[47]<\/sup><\/a><\/sup><\/p>\n<\/div>\n<p>A SBON may take disciplinary action against a nurse&#8217;s license for many reasons. Common reasons related to medication administration include, but are not limited to, the following:<\/p>\n<ul>\n<li>Noncompliance with federal, jurisdictional, or reporting requirements, including practicing beyond the scope of practice.<\/li>\n<li>Confidentiality, client privacy, consent, or disclosure violations.<\/li>\n<li>Fraud, deception or misrepresentation, including falsification of client documentation.<\/li>\n<li>Unsafe practice or substandard care, including:\n<ul>\n<li>Failing to perform nursing care with reasonable skill and safety.<\/li>\n<li>Departing from or failing to conform to the minimal standards of acceptable nursing practice that may create unnecessary risk or danger to a client&#8217;s life, health, or safety. Actual injury to a client does not need to be established.<\/li>\n<li>Failing to report to or leaving a nursing assignment without properly notifying appropriate supervisory personnel and ensuring the safety and welfare of the client.<\/li>\n<li>Practicing nursing while under the influence of alcohol, illicit drugs, or while impaired by the use of legitimately prescribed pharmacological agents or medications.<\/li>\n<li>Inability to practice safely due to alcohol or other substance use, psychological or physical illness, or impairment.<\/li>\n<li>Executing an order which the licensee knew or should have known could harm a client.<\/li>\n<\/ul>\n<\/li>\n<li>Improper supervision.<\/li>\n<li>Improper prescribing, dispensing, or administering medication or drug-related offenses.<sup><a class=\"footnote\" title=\"Wisconsin Department of Safety and Professional Services. (n.d.). Wisconsin nurse practice act (NPA) course. https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" id=\"return-footnote-69-48\" href=\"#footnote-69-48\" aria-label=\"Footnote 48\"><sup class=\"footnote\">[48]<\/sup><\/a><\/sup><\/li>\n<\/ul>\n<h3><a id=\"_m6j5wqv1r3pq\" href=\"\"><\/a>State Statutes Related to Controlled Substances<\/h3>\n<p><a id=\"_2dtqojbdakka\" href=\"\"><\/a>In addition to the NPA, there are other state statutes that guide nursing care and medication administration. State statutes are a compilation of the general laws of the state and often include chapters related to the state regulation of controlled substances (in addition to federal law previously discussed in this section).<\/p>\n<div class=\"textbox\">\n<p class=\"arrow\">View an <a href=\"https:\/\/docs.legis.wisconsin.gov\/statutes\/statutes\/961\" target=\"_blank\" rel=\"noopener\">example of state regulation of controlled substances<\/a> in Wisconsin Chapter 961: Uniform Controlled Substances Act.<\/p>\n<\/div>\n<h4><a id=\"_vx88vyc3zvqo\" href=\"\"><\/a>Prescription Drug Monitoring Program<\/h4>\n<p>Examples of state law related to controlled substances are prescription drug monitoring programs (PDMP). Many states have implemented PDMP to help combat the ongoing prescription substance abuse epidemic, as well as to help prevent drug diversion. Pharmacies and health care providers are often required by state law to participate in a PDMP when dispensing or prescribing controlled substances. A PDMP is a statewide electronic database that collects data on substances dispensed in the state. By providing valuable information about controlled substance prescriptions that are dispensed in the state, PDMPs help health care providers make prescribing and dispensing decisions. PDMPs also foster the ability of pharmacies, health care professionals, law enforcement agencies, and public health officials to work together to reduce the misuse, abuse, and diversion of prescribed controlled substances.<\/p>\n<div class=\"textbox\">\n<p class=\"arrow\">View <a href=\"https:\/\/pdmp.wi.gov\" target=\"_blank\" rel=\"noopener\">Wisconsin&#8217;s Enhanced Prescription Drug Monitoring Program (ePDMP)<\/a><sup><a class=\"footnote\" title=\"Wisconsin ePDMP. (2019). https:\/\/pdmp.wi.gov\/\" id=\"return-footnote-69-49\" href=\"#footnote-69-49\" aria-label=\"Footnote 49\"><sup class=\"footnote\">[49]<\/sup><\/a><\/sup><\/p>\n<\/div>\n<h4><a id=\"_cpals5n9c270\" href=\"\"><\/a>Professional Assistance Programs<\/h4>\n<p>In addition to state statutes related to controlled substances, many states offer professional assistance programs as voluntary, nondisciplinary programs to provide support for health professionals with substance abuse disorders (SUD) who are committed to their own recovery. The goal of professional assistance programs is to protect the public by promoting early identification of professionals with SUD and encouraging their rehabilitation and recovery. Professional assistance programs provide an opportunity for nurses with SUD to continue to be employed while being monitored by the SBON and supported in their recovery.<\/p>\n<div class=\"textbox\">\n<p class=\"arrow\">View <a href=\"https:\/\/pdmp.wi.gov\" target=\"_blank\" rel=\"noopener\">Wisconsin&#8217;s Professional Assistance Program<\/a>.<sup><a class=\"footnote\" title=\"Wisconsin Department of Safety and Professional Services. (n.d.). Wisconsin nurse practice act (NPA) course. https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" id=\"return-footnote-69-50\" href=\"#footnote-69-50\" aria-label=\"Footnote 50\"><sup class=\"footnote\">[50]<\/sup><\/a>\u00a0<\/sup><\/p>\n<\/div>\n<div class=\"__UNKNOWN__\">\n<div class=\"textbox textbox--examples\">\n<header class=\"textbox__header\">\n<h2>Critical Thinking Activity 2.3d<img loading=\"lazy\" decoding=\"async\" class=\"alignright size-thumbnail wp-image-67\" src=\"https:\/\/pressbooks.ccconline.org\/accdigitalmarketing\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-150x150.png\" alt=\"Image of a circle containing a speech bubble with a question mark in it.\" width=\"150\" height=\"150\" srcset=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-150x150.png 150w, https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-65x65.png 65w, https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1-225x225.png 225w, https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-content\/uploads\/sites\/219\/2019\/10\/ORN-Icons_internet-copy_internet-copy-300x300-1.png 300w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/h2>\n<\/header>\n<div class=\"textbox__content\" style=\"text-align: left\">\n<p>A nurse is disciplined by the Wisconsin Board of Nursing for an incident reported by her employer that she arrived at her shift intoxicated. The nurse shares with a nursing colleague, \u201cI love taking care of patients. I worked so hard to obtain my nursing license &#8211; I don&#8217;t want to lose it. I know my drinking has gotten out of control, but I don&#8217;t know where to turn.\u201d<\/p>\n<p>What is the best advice by the nursing colleague for this nurse with a drinking problem?<\/p>\n<p>Note: Answers to the Critical Thinking activities can be found in the \u201c<a href=\"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/chapter-2\/\" target=\"_blank\" rel=\"noopener\">Answer Key<\/a>\u201d section at the end of the book.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<hr class=\"before-footnotes clear\" \/><div class=\"footnotes\"><ol><li id=\"footnote-69-1\">U.S. Food and Drug Administration. (n.d). <a href=\"https:\/\/www.fda.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.fda.gov<\/a> <a href=\"#return-footnote-69-1\" class=\"return-footnote\" aria-label=\"Return to footnote 1\">&crarr;<\/a><\/li><li id=\"footnote-69-2\">U.S. Food and Drug Administration. (n.d.). <em>Developing new drugs.<\/em> <a href=\"https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs<\/a> <a href=\"#return-footnote-69-2\" class=\"return-footnote\" aria-label=\"Return to footnote 2\">&crarr;<\/a><\/li><li id=\"footnote-69-3\">This work is a derivative of <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\" target=\"_blank\" rel=\"noopener noreferrer\">DailyMed<\/a> by <a href=\"https:\/\/www.nlm.nih.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a> in the <a href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\" target=\"_blank\" rel=\"noopener noreferrer\">Public Domain<\/a>. <a href=\"#return-footnote-69-3\" class=\"return-footnote\" aria-label=\"Return to footnote 3\">&crarr;<\/a><\/li><li id=\"footnote-69-4\">U.S. Department of Justice - Drug Enforcement Administration. (n.d.). <em>Drug scheduling. <\/em><a href=\"https:\/\/www.dea.gov\/drug-scheduling\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.dea.gov\/drug-scheduling<\/a> <a href=\"#return-footnote-69-4\" class=\"return-footnote\" aria-label=\"Return to footnote 4\">&crarr;<\/a><\/li><li id=\"footnote-69-5\">Wisconsin Administrative Code. (2022).\u00a0<\/span><em style=\"font-size: 12.8px\">Uniform Controlled Substances Act.\u00a0<\/em><a style=\"font-size: 12.8px\" href=\"https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/phar\/8.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/phar\/8.pdf<\/a><span style=\"font-size: 12.8px\"> <a href=\"#return-footnote-69-5\" class=\"return-footnote\" aria-label=\"Return to footnote 5\">&crarr;<\/a><\/li><li id=\"footnote-69-6\">U.S. Department of Justice - Drug Enforcement Administration. (n.d.). <em>Drug scheduling.<\/em> <a href=\"https:\/\/www.dea.gov\/drug-scheduling\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.dea.gov\/drug-scheduling<\/a> <a href=\"#return-footnote-69-6\" class=\"return-footnote\" aria-label=\"Return to footnote 6\">&crarr;<\/a><\/li><li id=\"footnote-69-7\">U.S. Department of Justice - Drug Enforcement Administration. (n.d.). <em>Drug scheduling. <\/em><a href=\"https:\/\/www.dea.gov\/drug-scheduling\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.dea.gov\/drug-scheduling<\/a> <a href=\"#return-footnote-69-7\" class=\"return-footnote\" aria-label=\"Return to footnote 7\">&crarr;<\/a><\/li><li id=\"footnote-69-8\">U.S. Department of Justice - Drug Enforcement Administration. (2023).<em> Controlled substances. <\/em><a href=\"https:\/\/www.deadiversion.usdoj.gov\/schedules\/orangebook\/c_cs_alpha.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.deadiversion.usdoj.gov\/schedules\/orangebook\/c_cs_alpha.pdf<\/a> <a href=\"#return-footnote-69-8\" class=\"return-footnote\" aria-label=\"Return to footnote 8\">&crarr;<\/a><\/li><li id=\"footnote-69-9\">U.S. Department of Justice - Drug Enforcement Administration. (2023). <em>Controlled substances. <\/em><a href=\"https:\/\/www.deadiversion.usdoj.gov\/schedules\/orangebook\/c_cs_alpha.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.deadiversion.usdoj.gov\/schedules\/orangebook\/c_cs_alpha.pdf<\/a> <a href=\"#return-footnote-69-9\" class=\"return-footnote\" aria-label=\"Return to footnote 9\">&crarr;<\/a><\/li><li id=\"footnote-69-10\">New, K. (2014, June 3). <em>Drug diversion defined: A patient safety threat.<\/em> Centers for Disease Control and Prevention. <a href=\"https:\/\/web.archive.org\/web\/20150716073835\/http:\/\/blogs.cdc.gov\/safehealthcare\/2014\/06\/03\/drug-diversion-defined-a-patient-safety-threat\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/web.archive.org\/web\/20150716073835\/http:\/\/blogs.cdc.gov\/safehealthcare\/2014\/06\/03\/drug-diversion-defined-a-patient-safety-threat\/<\/a> <a href=\"#return-footnote-69-10\" class=\"return-footnote\" aria-label=\"Return to footnote 10\">&crarr;<\/a><\/li><li id=\"footnote-69-11\">Berge, K. H., Dillon, K. R., Sikkink, K. M., Taylor, T. K., &amp; Lanier, W. L. (2012). Diversion of drugs within health care facilities, a multiple-victim crime: Patterns of diversion, scope, consequences, detection, and prevention. <em>Mayo Clinic Proceedings, 87<\/em>(7), 674\u2013682. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22766087\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22766087<\/a> <a href=\"#return-footnote-69-11\" class=\"return-footnote\" aria-label=\"Return to footnote 11\">&crarr;<\/a><\/li><li id=\"footnote-69-12\">U.S. Department of Justice - Drug Enforcement Administration. (n.d.). <a href=\"https:\/\/www.deadiversion.usdoj.gov\/prog_dscrpt\/index.html\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.deadiversion.usdoj.gov\/prog_dscrpt\/index.html<\/a> <a href=\"#return-footnote-69-12\" class=\"return-footnote\" aria-label=\"Return to footnote 12\">&crarr;<\/a><\/li><li id=\"footnote-69-13\">U.S. Department of Justice - Drug Enforcement Administration. (n.d.). <em>RX abuse online reporting: Report incident.<\/em> <a href=\"https:\/\/apps2.deadiversion.usdoj.gov\/rxaor\/spring\/main?execution=e1s1\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/apps2.deadiversion.usdoj.gov\/rxaor\/spring\/main?execution=e1s1<\/a> <a href=\"#return-footnote-69-13\" class=\"return-footnote\" aria-label=\"Return to footnote 13\">&crarr;<\/a><\/li><li id=\"footnote-69-14\">American Psychiatric Association. (2013). <em>Desk reference to the diagnostic criteria from DSM-5<\/em>. <a href=\"#return-footnote-69-14\" class=\"return-footnote\" aria-label=\"Return to footnote 14\">&crarr;<\/a><\/li><li id=\"footnote-69-15\">National Council of State Boards of Nursing (NCSBN). (2018). <em>A nurse's guide to substance use disorder in nursing.<\/em> <a href=\"https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf<\/a> <a href=\"#return-footnote-69-15\" class=\"return-footnote\" aria-label=\"Return to footnote 15\">&crarr;<\/a><\/li><li id=\"footnote-69-16\">National Council of State Boards of Nursing (NCSBN). (2018). <em>A nurse's guide to substance use disorder in nursing.<\/em> <a href=\"https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf<\/a> <a href=\"#return-footnote-69-16\" class=\"return-footnote\" aria-label=\"Return to footnote 16\">&crarr;<\/a><\/li><li id=\"footnote-69-17\">National Council of State Boards of Nursing (NCSBN). (2018). <em>A nurse's guide to substance use disorder in nursing.<\/em> <a href=\"https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ncsbn.org\/public-files\/SUD_Brochure_2014.pdf<\/a> <a href=\"#return-footnote-69-17\" class=\"return-footnote\" aria-label=\"Return to footnote 17\">&crarr;<\/a><\/li><li id=\"footnote-69-18\">U.S. Department of Justice - Drug Enforcement Administration. (2017, December 13). <em>Federal regulations and the disposal of controlled substances. <\/em><a href=\"https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal<\/a> <a href=\"#return-footnote-69-18\" class=\"return-footnote\" aria-label=\"Return to footnote 18\">&crarr;<\/a><\/li><li id=\"footnote-69-19\">U.S. Department of Justice - Drug Enforcement Administration. (2017, December 13). <em>Federal regulations and the disposal of controlled substances.<\/em> <a href=\"https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal<\/a> <a href=\"#return-footnote-69-19\" class=\"return-footnote\" aria-label=\"Return to footnote 19\">&crarr;<\/a><\/li><li id=\"footnote-69-20\">\u201cMedRx box.JPG\u201d by <a href=\"https:\/\/www.yorkpolice.org\/163\/Town-of-York-Police-Department\" target=\"_blank\" rel=\"noopener noreferrer\">York Police<\/a> is licensed under <a href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/cc0\/\" target=\"_blank\" rel=\"noopener noreferrer\">CC0<\/a> <a href=\"#return-footnote-69-20\" class=\"return-footnote\" aria-label=\"Return to footnote 20\">&crarr;<\/a><\/li><li id=\"footnote-69-21\">U.S. Department of Justice - Drug Enforcement Administration. (2017, December 13). <em>Federal regulations and the disposal of controlled substances. <\/em><a href=\"https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal\">https:\/\/www.deadiversion.usdoj.gov\/mtgs\/drug_chemical\/2017\/wingert.pdf#search=drug%20disposal<\/a> <a href=\"#return-footnote-69-21\" class=\"return-footnote\" aria-label=\"Return to footnote 21\">&crarr;<\/a><\/li><li id=\"footnote-69-22\">The Joint Commission. (n.d.). <a href=\"https:\/\/www.jointcommission.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.jointcommission.org\/<\/a> <a href=\"#return-footnote-69-22\" class=\"return-footnote\" aria-label=\"Return to footnote 22\">&crarr;<\/a><\/li><li id=\"footnote-69-23\">Joint Commission Center for Transforming Healthcare. (2020). <em>Hand hygiene.<\/em> <a href=\"https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/hand-hygiene\" target=\"_blank\" rel=\"noopener\">https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/hand-hygiene<\/a> <a href=\"#return-footnote-69-23\" class=\"return-footnote\" aria-label=\"Return to footnote 23\">&crarr;<\/a><\/li><li id=\"footnote-69-24\">Joint Commission Center for Transforming Healthcare. (2020.) <em>Effective hand-off communications.<\/em> <a href=\"https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/hand-off-communications\" target=\"_blank\" rel=\"noopener\">https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/hand-off-communications<\/a> <a href=\"#return-footnote-69-24\" class=\"return-footnote\" aria-label=\"Return to footnote 24\">&crarr;<\/a><\/li><li id=\"footnote-69-25\">Joint Commission Center for Transforming Healthcare. (2020). <em>Safe and effective use of insulin<\/em>. <a href=\"https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/safe-and-effective-use-of-insulin\" target=\"_blank\" rel=\"noopener\">https:\/\/www.centerfortransforminghealthcare.org\/improvement-topics\/safe-and-effective-use-of-insulin<\/a> <a href=\"#return-footnote-69-25\" class=\"return-footnote\" aria-label=\"Return to footnote 25\">&crarr;<\/a><\/li><li id=\"footnote-69-26\">The Joint Commission. (2014, November). <em>Facts about the safety culture project.<\/em> <a href=\"https:\/\/www.centerfortransforminghealthcare.org\/-\/media\/cth\/documents\/improvement-topics\/cth_sc_fact_sheet.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.centerfortransforminghealthcare.org\/-\/media\/cth\/documents\/improvement-topics\/cth_sc_fact_sheet.pdf<\/a> <a href=\"#return-footnote-69-26\" class=\"return-footnote\" aria-label=\"Return to footnote 26\">&crarr;<\/a><\/li><li id=\"footnote-69-27\">Patient Safety Network. (2019). <em>Root cause analysis.<\/em> <a href=\"https:\/\/psnet.ahrq.gov\/primer\/root-cause-analysis\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/psnet.ahrq.gov\/primer\/root-cause-analysis<\/a> <a href=\"#return-footnote-69-27\" class=\"return-footnote\" aria-label=\"Return to footnote 27\">&crarr;<\/a><\/li><li id=\"footnote-69-28\">Institute for Safe Medication Practices. (2007, November 29). <em>Another heparin error: Learning from mistakes so we don't repeat them.<\/em> <a href=\"https:\/\/www.ismp.org\/resources\/another-heparin-error-learning-mistakes-so-we-dont-repeat-them\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.ismp.org\/resources\/another-heparin-error-learning-mistakes-so-we-dont-repeat-them<\/a> <a href=\"#return-footnote-69-28\" class=\"return-footnote\" aria-label=\"Return to footnote 28\">&crarr;<\/a><\/li><li id=\"footnote-69-29\">The Joint Commission. (n.d.). <em>Speak up campaigns. <a href=\"https:\/\/www.jointcommission.org\/resources\/for-consumers\/speak-up-campaigns\/#sort=%40z95xz95xcontentdate%20descending\" target=\"_blank\" rel=\"noopener\">https:\/\/www.jointcommission.org\/resources\/for-consumers\/speak-up-campaigns\/#sort=%40z95xz95xcontentdate%20descending<\/a><\/em> <a href=\"#return-footnote-69-29\" class=\"return-footnote\" aria-label=\"Return to footnote 29\">&crarr;<\/a><\/li><li id=\"footnote-69-30\">The Joint Commission. (2023). <em>2023 hospital national patient safety goals.<\/em> <a href=\"https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf<\/a> <a href=\"#return-footnote-69-30\" class=\"return-footnote\" aria-label=\"Return to footnote 30\">&crarr;<\/a><\/li><li id=\"footnote-69-31\">The Joint Commission. (2023). <em>2023 hospital national patient safety goals.<\/em> <a href=\"https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf<\/a> <a href=\"#return-footnote-69-31\" class=\"return-footnote\" aria-label=\"Return to footnote 31\">&crarr;<\/a><\/li><li id=\"footnote-69-32\">The Joint Commission. (2023). <em>2023 hospital national patient safety goals<\/em>. <a href=\"https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf<\/a> <a href=\"#return-footnote-69-32\" class=\"return-footnote\" aria-label=\"Return to footnote 32\">&crarr;<\/a><\/li><li id=\"footnote-69-33\">The Joint Commission. (2023). <em>2023 hospital national patient safety goals<\/em>. <a href=\"https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.jointcommission.org\/assets\/1\/6\/2019_HAP_NPSGs_final2.pdf<\/a> <a href=\"#return-footnote-69-33\" class=\"return-footnote\" aria-label=\"Return to footnote 33\">&crarr;<\/a><\/li><li id=\"footnote-69-34\">The Joint Commission. (2023). <em>Do not use list fact sheet.<\/em> <a href=\"https:\/\/www.jointcommission.org\/facts_about_do_not_use_list\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.jointcommission.org\/facts_about_do_not_use_list\/<\/a> <a href=\"#return-footnote-69-34\" class=\"return-footnote\" aria-label=\"Return to footnote 34\">&crarr;<\/a><\/li><li id=\"footnote-69-35\">U.S. Department of Health &amp; Human Services, Centers for Medicare &amp; Medicaid Services. (2014). <em>Memo: Requirements for hospital medication administration, particularly intravenous (IV) medications and post-operative care of patients receiving IV opioids<\/em>. <a href=\"https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf<\/a> <a href=\"#return-footnote-69-35\" class=\"return-footnote\" aria-label=\"Return to footnote 35\">&crarr;<\/a><\/li><li id=\"footnote-69-36\">American Nurses Association. (2021). <em>ANA issue brief: Use of medication assistants\/aides\/technicians.<\/em> <a href=\"https:\/\/www.nursingworld.org\/~498e32\/contentassets\/a2ff1bd2d5ca467699c3bc764f7d9198\/issue-brief-medication-aides-4-2021.docx\" target=\"_blank\" rel=\"noopener\">https:\/\/www.nursingworld.org\/~498e32\/contentassets\/a2ff1bd2d5ca467699c3bc764f7d9198\/issue-brief-medication-aides-4-2021.docx<\/a> <a href=\"#return-footnote-69-36\" class=\"return-footnote\" aria-label=\"Return to footnote 36\">&crarr;<\/a><\/li><li id=\"footnote-69-37\">Kimberly Dunker. (2020, April 6). <em>Mediation Administration. <\/em>[Video]. YouTube. All rights reserved. <a href=\"https:\/\/youtu.be\/MUn4Ec2X93g\" target=\"_blank\" rel=\"noopener\">https:\/\/youtu.be\/MUn4Ec2X93g<\/a> <a href=\"#return-footnote-69-37\" class=\"return-footnote\" aria-label=\"Return to footnote 37\">&crarr;<\/a><\/li><li id=\"footnote-69-38\">U.S. Department of Health &amp; Human Services, Centers for Medicare &amp; Medicaid Services. (2014). <em>Memo: Requirements for hospital medication administration, particularly intravenous (IV) medications and post-operative care of patients receiving IV opioids<\/em>. <a href=\"https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf<\/a> <a href=\"#return-footnote-69-38\" class=\"return-footnote\" aria-label=\"Return to footnote 38\">&crarr;<\/a><\/li><li id=\"footnote-69-39\">U.S. Department of Health &amp; Human Services, Centers for Medicare &amp; Medicaid Services. (2014). <em>Memo: Requirements for hospital medication administration, particularly intravenous (IV) medications and post-operative care of patients receiving IV opioids<\/em>. <a href=\"https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf<\/a> <a href=\"#return-footnote-69-39\" class=\"return-footnote\" aria-label=\"Return to footnote 39\">&crarr;<\/a><\/li><li id=\"footnote-69-40\">U.S. Department of Health &amp; Human Services, Centers for Medicare &amp; Medicaid Services. (2014). <em>Memo: Requirements for hospital medication administration, particularly intravenous (IV) medications and post-operative care of patients receiving IV opioids<\/em>. <a href=\"https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Survey-and-Cert-Letter-14-15.pdf<\/a> <a href=\"#return-footnote-69-40\" class=\"return-footnote\" aria-label=\"Return to footnote 40\">&crarr;<\/a><\/li><li id=\"footnote-69-41\">American Society of Health-System Pharmacists (Ed.). (2018). ASHP guidelines on preventing medication errors in hospitals. <em>American Journal of Health-System Pharmacy, 75<\/em>, 1493\u20131517. <a href=\"https:\/\/www.ashp.org\/-\/media\/assets\/policy-guidelines\/docs\/guidelines\/preventing-medication-errors-hospitals.ashx\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.ashp.org\/-\/media\/assets\/policy-guidelines\/docs\/guidelines\/preventing-medication-errors-hospitals.ashx<\/a>  <a href=\"#return-footnote-69-41\" class=\"return-footnote\" aria-label=\"Return to footnote 41\">&crarr;<\/a><\/li><li id=\"footnote-69-42\">Wisconsin Department of Safety and Professional Services. (n.d.). <em>Wisconsin nurse practice act (NPA) course.<\/em> <a href=\"https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf<\/a> <a href=\"#return-footnote-69-42\" class=\"return-footnote\" aria-label=\"Return to footnote 42\">&crarr;<\/a><\/li><li id=\"footnote-69-43\">Wisconsin Department of Safety and Professional Services. (n.d.). <em>Wisconsin nurse practice act (NPA) course.<\/em> <a href=\"https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf<\/a> <a href=\"#return-footnote-69-43\" class=\"return-footnote\" aria-label=\"Return to footnote 43\">&crarr;<\/a><\/li><li id=\"footnote-69-44\">Wisconsin Department of Safety and Professional Services. (n.d.). <em>Wisconsin nurse practice act (NPA) course.<\/em> <a href=\"https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf<\/a> <a href=\"#return-footnote-69-44\" class=\"return-footnote\" aria-label=\"Return to footnote 44\">&crarr;<\/a><\/li><li id=\"footnote-69-45\"><\/a>Wisconsin Department of Safety and Professional Services. (n.d.). <em>Board of nursing Wisconsin Administrative Code.<\/em>\u00a0<a class=\"rId37\" href=\"https:\/\/dsps.wi.gov\/Pages\/RulesStatutes\/Nursing.aspx\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Pages\/RulesStatutes\/Nursing.aspx <a href=\"#return-footnote-69-45\" class=\"return-footnote\" aria-label=\"Return to footnote 45\">&crarr;<\/a><\/li><li id=\"footnote-69-46\">Wisconsin Department of Safety and Professional Services. (n.d.). <em>Wisconsin nurse practice act (NPA) course.<\/em> <a href=\"https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf<\/a> <a href=\"#return-footnote-69-46\" class=\"return-footnote\" aria-label=\"Return to footnote 46\">&crarr;<\/a><\/li><li id=\"footnote-69-47\">Wisconsin State Legislature. (2016, August). <em>Chapter N7 rules of conduct. <\/em><a href=\"https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/n\/7.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/docs.legis.wisconsin.gov\/code\/admin_code\/n\/7.pdf<\/a> <a href=\"#return-footnote-69-47\" class=\"return-footnote\" aria-label=\"Return to footnote 47\">&crarr;<\/a><\/li><li id=\"footnote-69-48\">Wisconsin Department of Safety and Professional Services. (n.d.). <em>Wisconsin nurse practice act (NPA) course.<\/em> <a href=\"https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf<\/a> <a href=\"#return-footnote-69-48\" class=\"return-footnote\" aria-label=\"Return to footnote 48\">&crarr;<\/a><\/li><li id=\"footnote-69-49\">Wisconsin ePDMP. (2019). <a href=\"https:\/\/pdmp.wi.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/pdmp.wi.gov\/<\/a> <a href=\"#return-footnote-69-49\" class=\"return-footnote\" aria-label=\"Return to footnote 49\">&crarr;<\/a><\/li><li id=\"footnote-69-50\">Wisconsin Department of Safety and Professional Services. (n.d.). <em>Wisconsin nurse practice act (NPA) course.<\/em> <a href=\"https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/dsps.wi.gov\/Documents\/BoardCouncils\/NUR\/20190110NURAdditionalMaterials.pdf<\/a> <a href=\"#return-footnote-69-50\" class=\"return-footnote\" aria-label=\"Return to footnote 50\">&crarr;<\/a><\/li><\/ol><\/div><div class=\"glossary\"><span class=\"screen-reader-text\" id=\"definition\">definition<\/span><template id=\"term_69_623\"><div class=\"glossary__definition\" role=\"dialog\" data-id=\"term_69_623\"><div tabindex=\"-1\"><p>The strongest warnings issued by the Federal Drug Association (FDA) that signify a drug carries a significant risk of serious or life-threatening adverse effects.<\/p>\n<\/div><button><span aria-hidden=\"true\">&times;<\/span><span class=\"screen-reader-text\">Close definition<\/span><\/button><\/div><\/template><template id=\"term_69_723\"><div class=\"glossary__definition\" role=\"dialog\" data-id=\"term_69_723\"><div tabindex=\"-1\"><p>A national organization that accredits and certifies over 20,000 health care organizations in the United States.<\/p>\n<\/div><button><span aria-hidden=\"true\">&times;<\/span><span class=\"screen-reader-text\">Close definition<\/span><\/button><\/div><\/template><template id=\"term_69_625\"><div class=\"glossary__definition\" role=\"dialog\" data-id=\"term_69_625\"><div tabindex=\"-1\"><p><strong>\u00a0<\/strong>The culture of a health care agency that empowers staff to speak up about risks to patients and to report errors and near misses, all of which drive improvement in patient care and reduce the incident of patient harm.<\/p>\n<\/div><button><span aria-hidden=\"true\">&times;<\/span><span class=\"screen-reader-text\">Close definition<\/span><\/button><\/div><\/template><template id=\"term_69_548\"><div class=\"glossary__definition\" role=\"dialog\" data-id=\"term_69_548\"><div tabindex=\"-1\"><p>An analysis after an error occurs to help identify not only what and how an event occurred, but also why it happened. When investigators are able to determine why an event or failure occurred, they can create workable corrective measures that prevent future errors from occurring.<\/p>\n<\/div><button><span aria-hidden=\"true\">&times;<\/span><span class=\"screen-reader-text\">Close definition<\/span><\/button><\/div><\/template><template id=\"term_69_549\"><div class=\"glossary__definition\" role=\"dialog\" data-id=\"term_69_549\"><div tabindex=\"-1\"><p>Goals established by The Joint Commission to help accredited organizations address specific areas of concern related to patient safety.<\/p>\n<\/div><button><span aria-hidden=\"true\">&times;<\/span><span class=\"screen-reader-text\">Close definition<\/span><\/button><\/div><\/template><template id=\"term_69_626\"><div class=\"glossary__definition\" role=\"dialog\" data-id=\"term_69_626\"><div tabindex=\"-1\"><p>Standards of Practice that include Assessment, Diagnosis, Outcome Identification, Planning, Implementation, and Evaluation components of providing patient care.<\/p>\n<\/div><button><span aria-hidden=\"true\">&times;<\/span><span class=\"screen-reader-text\">Close definition<\/span><\/button><\/div><\/template><\/div>","protected":false},"author":83,"menu_order":3,"template":"","meta":{"pb_show_title":"on","pb_short_title":"","pb_subtitle":"","pb_authors":[],"pb_section_license":""},"chapter-type":[48],"contributor":[],"license":[],"class_list":["post-69","chapter","type-chapter","status-publish","hentry","chapter-type-numberless"],"part":61,"_links":{"self":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/69","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters"}],"about":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/types\/chapter"}],"author":[{"embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/users\/83"}],"version-history":[{"count":2,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/69\/revisions"}],"predecessor-version":[{"id":742,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/69\/revisions\/742"}],"part":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/parts\/61"}],"metadata":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/69\/metadata\/"}],"wp:attachment":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/media?parent=69"}],"wp:term":[{"taxonomy":"chapter-type","embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapter-type?post=69"},{"taxonomy":"contributor","embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/contributor?post=69"},{"taxonomy":"license","embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/license?post=69"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}